<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="review-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">674682</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.674682</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Bioactive Compounds as Potential Agents for Sexually Transmitted Diseases Management: A Review to Explore Molecular Mechanisms of Action</article-title>
<alt-title alt-title-type="left-running-head">Sharifi-Rad et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Bio-Compounds Against Sexually Transmitted Pathogens</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Sharifi-Rad</surname>
<given-names>Javad</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/160127/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Quispe</surname>
<given-names>Cristina</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1069762/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rahavian</surname>
<given-names>Amirhossein</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1016389/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pereira Carneiro</surname>
<given-names>Joara N&#xe1;lyda</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rocha</surname>
<given-names>Jana&#xed;na Esmeraldo</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alves Borges Leal</surname>
<given-names>Ant&#xf4;nio Linkoln</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1258967/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bezerra Morais Braga</surname>
<given-names>Maria Flaviana</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/188544/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Melo Coutinho</surname>
<given-names>Henrique Douglas</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/298388/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ansari Djafari</surname>
<given-names>Anahita</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alarc&#xf3;n-Zapata</surname>
<given-names>Pedro</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1251823/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martorell</surname>
<given-names>Miquel</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/990095/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Antika</surname>
<given-names>Gizem</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1258502/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tumer</surname>
<given-names>Tugba Boyunegmez</given-names>
</name>
<xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cruz-Martins</surname>
<given-names>Nat&#xe1;lia</given-names>
</name>
<xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref>
<xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref>
<xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/713521/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Helon</surname>
<given-names>Pawe&#x142;</given-names>
</name>
<xref ref-type="aff" rid="aff14">
<sup>14</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paprocka</surname>
<given-names>Paulina</given-names>
</name>
<xref ref-type="aff" rid="aff15">
<sup>15</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1368527/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Koch</surname>
<given-names>Wojciech</given-names>
</name>
<xref ref-type="aff" rid="aff16">
<sup>16</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1003741/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Docea</surname>
<given-names>Anca Oana</given-names>
</name>
<xref ref-type="aff" rid="aff17">
<sup>17</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1056189/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Calina</surname>
<given-names>Daniela</given-names>
</name>
<xref ref-type="aff" rid="aff18">
<sup>18</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/430074/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Facultad de Ciencias de La Salud, Universidad Arturo Prat, <addr-line>Iquique</addr-line>, <country>Chile</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Andrology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, <addr-line>Yazd</addr-line>, <country>Iran</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Universidade Regional Do Cariri - URCA. Cel Ant&#xf4;nio Luis, <addr-line>Crato-CE</addr-line>, <country>Brazil</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Department of Urology, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, <addr-line>Tehran</addr-line>, <country>Iran</country>
</aff>
<aff id="aff6">
<label>
<sup>6</sup>
</label>Clinical Biochemistry and Immunology Department, Faculty of Pharmacy, University of Concepci&#xf3;n, <addr-line>Concepci&#xf3;n</addr-line>, <country>Chile</country>
</aff>
<aff id="aff7">
<label>
<sup>7</sup>
</label>Facultad de Ciencias de la Salud, Universidad San Sebasti&#xe1;n, <addr-line>Concepci&#xf3;n</addr-line>, <country>Chile</country>
</aff>
<aff id="aff8">
<label>
<sup>8</sup>
</label>Department of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepci&#xf3;n, <addr-line>Concepci&#xf3;n</addr-line>, <country>Chile</country>
</aff>
<aff id="aff9">
<label>
<sup>9</sup>
</label>Universidad de Concepci&#xf3;n, Unidad de Desarrollo Tecnol&#xf3;gico, UDT, <addr-line>Concepci&#xf3;n</addr-line>, <country>Chile</country>
</aff>
<aff id="aff10">
<label>
<sup>10</sup>
</label>Department of Molecular Biology and Genetics, Faculty of Arts and Science, Canakkale Onsekiz Mart University, <addr-line>Canakkale</addr-line>, <country>Turkey</country>
</aff>
<aff id="aff11">
<label>
<sup>11</sup>
</label>Faculty of Medicine, University of Porto, <addr-line>Porto</addr-line>, <country>Portugal</country>
</aff>
<aff id="aff12">
<label>
<sup>12</sup>
</label>Institute for Research and Innovation in Health (i3S), University of Porto, <addr-line>Porto</addr-line>, <country>Portugal</country>
</aff>
<aff id="aff13">
<label>
<sup>13</sup>
</label>Laboratory of Neuropsychophysiology, Faculty of Psychology and Education Sciences, University of Porto, <addr-line>Porto</addr-line>, <country>Portugal</country>
</aff>
<aff id="aff14">
<label>
<sup>14</sup>
</label>Branch in Sandomierz, Jan Kochanowski University of Kielce, <addr-line>Sandomierz</addr-line>, <country>Poland</country>
</aff>
<aff id="aff15">
<label>
<sup>15</sup>
</label>Department of Microbiology and Immunology, Institute of Medical Sciences, Collegium Medicum, Jan Kochanowski University in Kielce, <addr-line>Kielce</addr-line>, <country>Poland</country>
</aff>
<aff id="aff16">
<label>
<sup>16</sup>
</label>Chair and Department of Food and Nutrition, Medical University of Lublin, <addr-line>Lublin</addr-line>, <country>Poland</country>
</aff>
<aff id="aff17">
<label>
<sup>17</sup>
</label>Department of Toxicology, University of Medicine and Pharmacy of Craiova, <addr-line>Craiova</addr-line>, <country>Romania</country>
</aff>
<aff id="aff18">
<label>
<sup>18</sup>
</label>Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, <addr-line>Craiova</addr-line>, <country>Romania</country>
</aff>
<author-notes>
<corresp id="c001">&#x2a;Correspondence: Javad Sharifi-Rad, <email>javad.sharifirad@gmail.com</email>; Henrique Douglas Melo Coutinho, <email>hdmcoutinho@gmail.com</email>; Nat&#xe1;lia Cruz-Martins, <email>ncmartins@med.up.pt</email>; Wojciech Koch, <email>kochw@interia.pl</email>; Daniela Calina, <email>calinadaniela@gmail.com</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/109889/overview">David M. Pereira</ext-link>, University of Porto, Portugal</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/87702/overview">Juan Carlos Sep&#xfa;lveda-Arias</ext-link>, Technological University of Pereira, Colombia</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/916709/overview">Mohamed El-Shazly</ext-link>, Ain Shams University, Egypt</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>08</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>674682</elocation-id>
<history>
<date date-type="received">
<day>08</day>
<month>03</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>07</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Sharifi-Rad, Quispe, Rahavian, Pereira Carneiro, Rocha, Alves Borges Leal, Bezerra Morais Braga, Melo Coutinho, Ansari Djafari, Alarc&#xf3;n-Zapata, Martorell, Antika, Tumer, Cruz-Martins, Helon, Paprocka, Koch, Docea and Calina.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Sharifi-Rad, Quispe, Rahavian, Pereira Carneiro, Rocha, Alves Borges Leal, Bezerra Morais Braga, Melo Coutinho, Ansari Djafari, Alarc&#xf3;n-Zapata, Martorell, Antika, Tumer, Cruz-Martins, Helon, Paprocka, Koch, Docea and Calina</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Sexually transmitted diseases (STDs) are produced by pathogens like bacteria, fungi, parasites, and viruses, and may generate severe health problems such as cancer, ulcers, and even problems in the newborn. This narrative review aims to present updated information about the use of natural bioactive compounds for the prevention and treatment of sexually transmitted infections. A search of the literature was performed using databases and search engines such as PubMed, Scopus, Google Scholar and Science Direct. From the pharmacotherapeutic management point of view, any strategies for prevention should contain medical approaches. The bioactive compounds obtained from natural products have shown biological effects against different microorganisms for the treatment of these diseases. The main results showed antimicrobial, antiprotozoal, antifungal and antiviral effects such as HIV. Also, the molecular mechanisms, signalling pathways and action targets of natural compounds were highlighted, thus justifying bacterial and antifungal inhibition, apoptosis or reduction of viral replication. From the data of our study, we can conclude that natural compounds may be a significant source for adjuvant drugs / complementary therapies in the treatment of STDs. With all these benefits, the future must conduct extensive clinical trials and the development of pharmaceutical nanotechnologies for a greater therapeutic effect.</p>
</abstract>
<kwd-group>
<kwd>pathogens</kwd>
<kwd>natural compounds</kwd>
<kwd>mechanisms</kwd>
<kwd>pharmacological effects</kwd>
<kwd>sexually transmitted diseases (STDs)</kwd>
<kwd>molecular targets</kwd>
<kwd>clinical studies</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>More than 30 different pathogens are responsible for diagnosing more than one million new cases of sexually transmitted diseases (STDs) daily worldwide, of which <italic>chlamydia</italic>, gonorrhoea, syphilis and trichomoniasis account for the largest share of STDs with 376 patients. millions of cases annually. (<xref ref-type="bibr" rid="B87">Newman et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B130">WHO, 2018</xref>). STDs are one of the health problems faced especially by developing countries, they usually affect young people of childbearing age, and can be transmitted to newborns during birth, the financial impact for these countries being overwhelming. (<xref ref-type="bibr" rid="B76">Mabey, 2010</xref>). STDs have existed for thousands of years, but the most dangerous of these conditions, Acquired Immune Deficiency Syndrome (AIDS), has been recognized since 1984. STDs can have severe complications, such as infertility, cancer, and pregnancy complications; they also had adverse effects on patients&#x27; psychosocial health and quality of life. In addition, some of these STDs may facilitate the transmission of HIV, so their control is one of the goals of the World Health Organization. (<xref ref-type="bibr" rid="B128">WHO, 2006</xref>; <xref ref-type="bibr" rid="B49">Gottlieb et&#x20;al., 2014</xref>). Species from the <italic>Candida</italic> genus are commensals and can under specific conditions, become opportunistic pathogens.</p>
<p>For the treatment of <italic>Candida albicans</italic>, essential oils (thyme, oregano, cloves) has traditionally been used, with natural antifungal, antibacterial and anti-inflammatory effects (<xref ref-type="bibr" rid="B107">Sharifi-Rad et&#x20;al., 2021</xref>). Over time, aloe vera has shown remarkable effects in eliminating bacterial STDs and decreasing inflammatory processes. A synergistic combination is aloe vera and honey, for an increased antibacterial effect against Trichomonas vaginalis infection and its symptoms (<xref ref-type="bibr" rid="B43">Friedman et&#x20;al., 2020</xref>). Mangosteen (<italic>Garcinia mangostana</italic>) is a fairly rare fruit that grows in Southeast Asia and has been used successfully in the treatment of gonorrhoea infections. The high concentration of vitamin C and antioxidants gives it strong antibacterial effects. Goldenseal is a medicinal plant native to North America. Goldenseal was used by the Cherokee Indians to treat common colds, infections, flu, gastrointestinal and urogenital diseases. Through its bioactive components, the plant has a strong antibacterial, antiviral, antifungal and antiparasitic action. It is thus a recommended alternative remedy for many diseases of a bacterial or viral nature, such as infections with HPV, <italic>C. trachomatis, C. albicans</italic> (<xref ref-type="bibr" rid="B72">Leyte-Lugo et&#x20;al., 2017</xref>). Starting from ethnopharmacological premises, many natural plant extracts/compounds have shown promising activity in combating chronic diseases, according to preliminary studies (<xref ref-type="bibr" rid="B99">Salehi et&#x20;al., 2021a</xref>; <xref ref-type="bibr" rid="B100">Salehi et&#x20;al., 2021b</xref>). Thus, polyphenolic compounds, alkaloids, isoflavonoid glycosides, oils, lipids, saponins and lactone sesquiterpenes have been shown. may have an anti-trichomoniasis effect in cell studies. (<xref ref-type="bibr" rid="B86">Naidoo et&#x20;al., 2013</xref>).</p>
<p>This work aims to present updated information about the use of natural bioactive compounds for the prevention and treatment of STDs. In this review, we illustrate the current landscape of bioactive natural compounds and their potential role in the future therapeutic armamentarium of&#x20;STDs.</p>
</sec>
<sec id="s2">
<title>Review Methodology</title>
<p>We performed research on PubMed, Scopus, Google Scholar and Science Direct using the MeSH terms: &#x201c;Sexually Transmitted Diseases&#x201d;, &#x201c;Bacterial&#x201d;, &#x201c;viral&#x201d;, &#x201c;HIV infection&#x201d;, &#x201c;classification&#x201d;, &#x201c;transmission&#x201d;, &#x201c;physiopathology&#x201d;, &#x201c;diagnosis&#x201d;, &#x201c;pharmacology&#x201d;, &#x201c;drug therapy&#x201d;, &#x201c;therapeutic use&#x201d;, &#x201c;plants/chemistry&#x201d;, &#x201c;humans&#x201d;.</p>
<p>Studies that highlighted the targets and molecular mechanisms of action of bioactive compounds with potential therapeutic effects in STDs were included (<xref ref-type="bibr" rid="B53">Heinrich et&#x20;al., 2020</xref>).</p>
<sec id="s2-1">
<title>Inclusion Criteria</title>
<p>
<list list-type="simple">
<list-item>
<p>1. <italic>in&#x20;vitro</italic> experimental pharmacological studies on cell&#x20;lines</p>
</list-item>
<list-item>
<p>2. studies with natural compounds and their derivatives in&#x20;STDs</p>
</list-item>
<list-item>
<p>3. studies that have highlighted the molecular mechanisms of action</p>
</list-item>
</list>
</p>
<p>Studies with homoeopathic preparations and without natural bioactive compounds and written in a language other than English were excluded. The taxonomy of plant species was made following The Plant List, and the chemical structures were validated using PubChem and SciFinder. All selected articles were analyzed for pharmacological research (<italic>in&#x20;vitro</italic>/<italic>in vivo</italic> studies, doses and results with mechanisms included), parts of plants used, bioactive compounds identified and their pharmacological properties against sexually transmitted pathogens. The most important mechanisms of action were represented in the figures together with the chemical structures and tables.</p>
</sec>
</sec>
<sec id="s3">
<title>An Overview of the Pathophysiology of Sexually Transmitted Diseases</title>
<p>We can divide STDs into curable and incurable infections. Major curable STDs, including <italic>chlamydia</italic>, gonorrhoea, syphilis, chancroid and trichomoniasis can be treated with appropriate antibiotics, but incurable infections such as genital herpes (HSV), warts (HPV) and HIV usually have long periods of evolution and there is no cure definite treatment for them. (<xref ref-type="bibr" rid="B76">Mabey, 2010</xref>; <xref ref-type="bibr" rid="B49">Gottlieb et&#x20;al., 2014</xref>). Using vaccines against HPV and HSV had a great influence in controlling these diseases (<xref ref-type="bibr" rid="B104">Schiller et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B129">WHO, 2012</xref>; <xref ref-type="bibr" rid="B7">Boda et&#x20;al., 2018</xref>) but there is still a high prevalence of STDs, especially in developing countries (<xref ref-type="bibr" rid="B20">Centers for Disease Control Prevention, 2011</xref>; <xref ref-type="bibr" rid="B49">Gottlieb et&#x20;al., 2014</xref>). Pathogens that cause sexually transmitted diseases are classified into several categories: bacterial, viral, fungal, and parasitic (<xref ref-type="table" rid="T1">Table&#x20;1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Etiological classification of the most common STDs.</p>
</caption>
<table>
<thead>
<tr>
<td align="left">Bacterial</td>
<td align="center">Viral</td>
<td align="center">Protozoal</td>
<td align="center">Fungal</td>
<td align="center">Ectoparasites</td>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>Neisseria gonorrhoeae</italic>
</td>
<td align="left">
<italic>Herpes simplex virus</italic>
</td>
<td rowspan="4" align="center">
<italic>Trichomonas vaginalis</italic>
</td>
<td rowspan="4" align="center">
<italic>Candida albicans</italic>
</td>
<td align="left">
<italic>Phthirius pubis</italic>
</td>
</tr>
<tr>
<td align="left">
<italic>Chlamydia trachomatis</italic>
</td>
<td align="left">
<italic>Human papilloma virus</italic>
</td>
<td align="left">
<italic>Sarcoptes scabiei</italic>
</td>
</tr>
<tr>
<td align="left">
<italic>Treponema pallidum</italic>
</td>
<td align="left">
<italic>HIV (AIDS)</italic>
</td>
<td align="left"/>
</tr>
<tr>
<td align="left">
<italic>Haemophilus ducreyi</italic>
</td>
<td align="left">Cytomegalovirus</td>
<td align="left"/>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s3-1">
<title>Bacteria</title>
<p>
<italic>Neisseria gonorrhoeae</italic> is a Gram-negative bacteria that responsible for gonorrhoea, the second most common STDs in&#x20;the United&#x20;States (US) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) (<xref ref-type="bibr" rid="B131">Workowski and Berman, 2011</xref>). Gonorrhoea causes urethral inflammation and in a rare&#x20;situation can be disseminated and produce meningitis, dermatitis, endocarditis, arthritis or surgical site infections (<xref ref-type="bibr" rid="B29">C&#x103;lina et&#x20;al., 2017</xref>). Nowadays performing nucleic acid amplification tests (NAATs) on urine (<xref ref-type="bibr" rid="B47">Geisler et&#x20;al., 2005</xref>) and culture of urethral swab specimens are introduced but NAATs are preferred due to higher sensitivity (<xref ref-type="bibr" rid="B46">Geisler, 2011</xref>) (<xref ref-type="bibr" rid="B119">Ungureanu et&#x20;al., 2017</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Summary about the major bacteria species that cause STDs (1. frequency for some region, 2. major symptoms, 3. major and possible health effects).</p>
</caption>
<graphic xlink:href="fphar-12-674682-g001.tif"/>
</fig>
<p>Chlamydial infections are the most common bacterial STDs in the world caused by <italic>C trachomatis</italic> (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). The chlamydial infection affected men and women and transmitted to infants during delivery than about 60&#x2013;70% of them became symptomatic (conjunctivitis). Traditionally, administration of doxycycline for one week was the choice of treatment but newer studies revealed that a single dose of azithromycin (1&#xa0;g) is as effective as doxycycline (<xref ref-type="bibr" rid="B73">Lister et&#x20;al., 1993</xref>) and nowadays azithromycin is a suitable choice.</p>
<p>
<italic>Haemophilus ducreyi</italic> is a Gram-negative bacteria that caused chancroid (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) (<xref ref-type="bibr" rid="B71">Lewis, 2003</xref>) and painful ulcer with unilateral inguinal lymphadenopathy are manifestations of it. It is difficult to diagnose chancroid by physical exam so some methods were introduced like culture and NAATs but there are not approved by the FDA. Antibiotic therapy is the main treatment and azithromycin, ceftriaxone, ciprofloxacin and erythromycin in different dosage were used (<xref ref-type="bibr" rid="B63">Kemp et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B131">Workowski and Berman, 2011</xref>).</p>
<p>
<italic>Treponema pallidum</italic> is responsible for syphilis (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) and is transmitted via micro abrasion of skin or mucosa (<xref ref-type="bibr" rid="B55">Ho&#x20;and Lukehart, 2011</xref>). There are different methods for diagnosis of syphilis one of them is identifying the <italic>T. pallidum</italic> from lesion samples under a dark field microscope (<xref ref-type="bibr" rid="B125">Wheeler et&#x20;al., 2004</xref>), Venereal disease Research Laboratory (VDRL), Rapid Plasma Reagin (RPR), Fluorescent Treponemal Antibody absorbed (FTA-ABS) or <italic>T. pallidum</italic> Particle Agglutination (TP-PA) are some serologic test that used (<xref ref-type="bibr" rid="B16">Calonge, 2004</xref>). Treatment of syphilis is antibiotic based and penicillin G in different dosages is the choice (<xref ref-type="bibr" rid="B131">Workowski and Berman, 2011</xref>).</p>
<p>Mycoplasmas are a large group that only <italic>mycoplasma</italic> and ureaplasma species are pathogenic for a human being (<xref ref-type="bibr" rid="B135">Zdrodowska-Stefanow et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B14">Calina et&#x20;al., 2016</xref>). These microorganisms are very small without cell wall and culture of them are very difficult so for detection, NAATs or PCR is choice but they are not available commercially (<xref ref-type="bibr" rid="B90">Palmer et&#x20;al., 1991</xref>; <xref ref-type="bibr" rid="B18">Cazanave et&#x20;al., 2012</xref>). Symptoms of infection included urethritis in both gender, cervicitis and lower abdominal pain in women (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) (<xref ref-type="bibr" rid="B117">Taylor-Robinson and Jensen, 2011</xref>; <xref ref-type="bibr" rid="B59">Jensen et&#x20;al., 2016</xref>) but less than half of patients developed symptoms (<xref ref-type="bibr" rid="B3">Anagrius et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B38">Falk et&#x20;al., 2005</xref>). Treatment is antibiotic based and azithromycin is a choice with a cure rate of about 95% (<xref ref-type="bibr" rid="B59">Jensen et&#x20;al., 2016</xref>).</p>
<p>
<italic>Klebsiella granulomatis</italic> is a Gram-negative bacterium that caused granuloma inguinale (Donovanosis) (<xref ref-type="bibr" rid="B115">Taheri et&#x20;al., 2021</xref>; <xref ref-type="bibr" rid="B138">Zlatian et&#x20;al., 2018</xref>) (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). This STD is rare in the US and Europe but in South Africa, India, Brazil and some part of Australia is endemic (<xref ref-type="bibr" rid="B67">Lagerg&#xe5;rd et&#x20;al., 2011</xref>; <xref ref-type="bibr" rid="B92">Pontari, 2016</xref>). About 50&#x20;days after exposure, symptoms appeared (<xref ref-type="bibr" rid="B88">O&#x2019;Farrell, 2002</xref>). At the site of infection (genitals and perineum) a painless papule appeared that progressed to ulcer and in 10% inguinal lymphadenopathy may occur. The ulcers are vascular rich so bleed easily (<xref ref-type="bibr" rid="B123">Velho et&#x20;al., 2008</xref>). Lymphadenopathy is uncommon but the inguinal ulcer is common and kissing ulcers on the inguinal fold are characteristic of this infection (<xref ref-type="bibr" rid="B95">Richens, 1991</xref>). Other areas that affected are gingivae, lips, mandible, abdomen, arm, leg and bone and oral lesions are more frequent (<xref ref-type="bibr" rid="B44">Galarza, 2000</xref>; <xref ref-type="bibr" rid="B94">Richens, 2006</xref>) that can cause loss of teeth due to mandible bone destruction (<xref ref-type="bibr" rid="B123">Velho et&#x20;al., 2008</xref>). Diagnosis is based on identifying Donovan bodies under a microscope after Wright, Giemsa or Leishman staining (<xref ref-type="bibr" rid="B94">Richens, 2006</xref>) and doxycycline are antibiotics of choice for treatment that should consume till all lesions disappeared (at least three weeks) (<xref ref-type="bibr" rid="B131">Workowski and Berman, 2011</xref>).</p>
</sec>
<sec id="s3-2">
<title>Fungus</title>
<p>Candidiasis is the most common fungal infection and <italic>Candida albicans</italic> is the most common species. (<xref ref-type="bibr" rid="B112">Sobel, 2014</xref>). There are some risk factors for candidiasis such as pregnancy, diabetes, consumption of antibiotics, contraceptive agents and steroids (<xref ref-type="bibr" rid="B45">Geiger and Foxman, 1996</xref>; <xref ref-type="bibr" rid="B113">Sobel, 2016</xref>). Diagnosis and treatment are empirical and oral azole derivatives appropriately (85&#x2013;90%) (<xref ref-type="bibr" rid="B111">Sobel et&#x20;al., 1995</xref>; <xref ref-type="bibr" rid="B6">Blostein et&#x20;al., 2017</xref>). Immunosuppression and uncontrolled diabetes are the most important risk factors of recurrent candidiasis and the causative yeast is usually non-<italic>C. albicans</italic> (<italic>Candida glabrata</italic>) (<xref ref-type="bibr" rid="B92">Pontari, 2016</xref>).</p>
</sec>
<sec id="s3-3">
<title>Parasites</title>
<p>
<italic>Sarcoptes scabiei</italic> is a mite that caused skin infection in about 300 million people per year (<xref ref-type="bibr" rid="B25">Chosidow, 2006</xref>). Mites can be also transmitted by contact with infected clothes and beds (<xref ref-type="bibr" rid="B9">Burkhart et&#x20;al., 2000</xref>) so this parasite can spread between family members. Typical scabies manifestations are scabious burrows and nodules that caused itching, especially at night. Permethrin creams 5%, ivermectin and lindane cream 1% is used for treatment. Lindane should be the last choice because its toxicity affected the central nervous system (CNS) and caused seizures and aplastic anaemia (<xref ref-type="bibr" rid="B25">Chosidow, 2006</xref>). This type has psoriasiform and warty lesions on the scalp, palm, soles and neck with less itching. The load of mites on these lesions are very high so this disease is very contagious (<xref ref-type="bibr" rid="B26">Chosidow, 2000</xref>; <xref ref-type="bibr" rid="B52">Hay et&#x20;al., 2012</xref>).</p>
<p>
<italic>Trichomonas vaginalis</italic> is protozoal that produces trichomoniasis, the most common curable STDs (<xref ref-type="bibr" rid="B60">Johnston and Mabey, 2008</xref>). More than 157 million new cases were reported worldwide per year and its incidence is increasing annually (<xref ref-type="bibr" rid="B127">WHO, 2001</xref>), its cause is that rate of asymptomatic patients in this disease is high so diagnosis, treatment and cutting transmission chain are difficult. Nowadays using PCR for diagnosis has been studied and the results are impressive and may replace the culture method in future (<xref ref-type="bibr" rid="B124">Wendel et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B28">Crucitti et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B64">Kissinger et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B132">Workowski, 2015</xref>). The selective treatment is represented by a single dose of metronidazole (MTZ) or tinidazole is enough but in immunocompromised patients consumption of MTZ for a longer period is recommended (<xref ref-type="bibr" rid="B64">Kissinger et&#x20;al., 2010</xref>). Latex agglutination test and PCR are the other methods that have greater sensitivity than culture but they are not approved yet (<xref ref-type="bibr" rid="B78">Mayta et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B28">Crucitti et&#x20;al., 2003</xref>).</p>
<p>Lice are parasites that affect all hairy areas of the body. This disease can affect both sexes of all ages and transmitted directly or indirectly through contact with clothing (<xref ref-type="bibr" rid="B26">Chosidow, 2000</xref>). In adults, this disease is classified as STD, but in children, it can be transmitted through individual contact with infected people, so it should not be considered a STD (<xref ref-type="bibr" rid="B26">Chosidow, 2000</xref>; <xref ref-type="bibr" rid="B89">Orion et&#x20;al., 2006</xref>). For treatment, permethrin 1% cream is the first choice, also infected clothes must be decontaminated (<xref ref-type="bibr" rid="B89">Orion et&#x20;al., 2006</xref>).</p>
</sec>
<sec id="s3-4">
<title>3.4. Viruses</title>
<p>HPV is the most common STDs in the world (<xref ref-type="bibr" rid="B24">Chesson et&#x20;al., 2014</xref>) Worldwide prevalence of genital HPV infection was about 630 million (9&#x2013;13%) and annually 6 million new cases were infected (<xref ref-type="bibr" rid="B19">Centers for Disease Control Prevention, 2007</xref>). There is no cure for HPV infection but most HPV infections are self-limited and the median time for clearance of cervical HPV in women and genital HPV in men is 9.4 and 7.5&#xa0;months accordingly (<xref ref-type="bibr" rid="B69">Lee et&#x20;al., 2012</xref>) and about 90% of low-risk HPV infections regressed within two years so the goals of treatment are: 1) decreasing symptoms and increasing quality of life, 2) reducing viral load to limit transmission and progression (<xref ref-type="bibr" rid="B40">Forcier and Musacchio, 2010</xref>). Some treatments are patient-applied like imiquimod 5% cream and podofilox 0.5% solution and some are provider-administered including cryotherapy, surgical therapy and laser therapy for bladder wart (<xref ref-type="bibr" rid="B92">Pontari, 2016</xref>). An important issue about HPV is that some types of this virus are the most significant risk factor for cervical cancer and based on this we can categorize HPV infection as low and high risk. Low-risk HPV types included types 11 and 6 that are responsible for 90% of genital warts and low-grade cervical cells changes (<xref ref-type="bibr" rid="B114">Stanley, 2007</xref>) and types 16 and 18 were categorized as high risk because associated with invasive and high grade cervical and anal carcinoma (<xref ref-type="bibr" rid="B84">Mu&#xf1;oz et&#x20;al., 2003</xref>). WHO reported about 570,000 new cases of cervical cancer in 2018 (<xref ref-type="bibr" rid="B126">WHO, 2019</xref>) and HPV DNA was present in more than 90% of invasive cervical cancer (<xref ref-type="bibr" rid="B23">Chan et&#x20;al., 2019</xref>) furthermore HPV infection caused other malignancies like oropharynx cancers (<xref ref-type="bibr" rid="B40">Forcier and Musacchio, 2010</xref>). To reduce the risk of cervical cancer secondary to HPV infection, immunization strategies are the most important goal. (<xref ref-type="bibr" rid="B40">Forcier and Musacchio, 2010</xref>; <xref ref-type="bibr" rid="B4">Beachler et&#x20;al., 2015</xref>). Nowadays, there are many types of platforms for obtaining vaccines (<xref ref-type="bibr" rid="B12">Calina et&#x20;al., 2020a</xref>; <xref ref-type="bibr" rid="B15">Calina et&#x20;al., 2020c</xref>), but after clinical studies (<xref ref-type="bibr" rid="B13">Calina et&#x20;al., 2020b</xref>), only three types of vaccines are available for HPV infection:<list list-type="simple">
<list-item>
<p>1) Cervarix: a two valent (2V) vaccine that immunized patients from HPV type 16,&#x20;18;</p>
</list-item>
<list-item>
<p>2) Gardasil: a four valent (4V) vaccine that covers HPV type 6,11,16,18;</p>
</list-item>
<list-item>
<p>3) Gardasil 9: a nine-valent (9V) vaccine that targets HPV type 6,11,16,18,31,33,45,52, and 58 (<xref ref-type="bibr" rid="B31">de martel et&#x20;al., 2017</xref>).</p>
</list-item>
</list>
</p>
<p>It is important to remember that the vaccines are designed for infection prevention not clearing so after tainting, their effect of decrease (<xref ref-type="bibr" rid="B33">Docea et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B13">Calina et&#x20;al., 2020b</xref>; <xref ref-type="bibr" rid="B66">Kostoff et&#x20;al., 2020</xref>). Herpes simplex virus (HSV)<bold>:</bold> HSV-1 and HSV-2 are two types of HSV caused by genital herpes and are the most common cause of genital ulcers (<xref ref-type="bibr" rid="B50">Gupta et&#x20;al., 2007</xref>). The worldwide prevalence of genital herpes in 2012 was estimated at 417 million that Africa with 150 million cases had the highest burden (<xref ref-type="bibr" rid="B74">Looker et&#x20;al., 2015</xref>), beside this high prevalence, HSV infection has no definite treatment furthermore many patients do not aware of their disease that increased risk of transmission (<xref ref-type="bibr" rid="B80">Mertz et&#x20;al., 1992</xref>; <xref ref-type="bibr" rid="B50">Gupta et&#x20;al., 2007</xref>) so prevention, diagnosis and treatment of this infection is very important.</p>
<p>HSV-2 infected the genital area only but HSV-1 caused oral herpes and about half of genital herpes (<xref ref-type="bibr" rid="B68">Langenberg et&#x20;al., 1999</xref>). Signs and symptoms of primary genital herpes are various: clusters of erythematous vesicles and papules appear (<xref ref-type="bibr" rid="B27">Corey et&#x20;al., 1983</xref>) after three weeks new lesions appeared and the older ones transformed to pustules and ulcers and finally, these ulcers crusted and healed (<xref ref-type="bibr" rid="B27">Corey et&#x20;al., 1983</xref>). Some patients may develop itching and burning sensation and others may develop malaise, fever and headache, also inguinal and femoral non-tender lymphadenopathy may occur (<xref ref-type="bibr" rid="B27">Corey et&#x20;al., 1983</xref>). Most of the patients have atypical lesions and also differentiation of HSV-1 from HSV-2 based on lesion appearance is impossible so diagnosis based on history and physical examination is not accurate so we need additional testing like viral culture, antigen testing and PCR for diagnosis subgrouping HSV (<xref ref-type="bibr" rid="B21">Centers for Disease Control Prevention, 2002</xref>). Herpes virus is incurable and current antiviral agents cannot eradicate the infection, so the aim of treatment is to the alleviation of symptoms, preventing complications like aseptic meningitis and decreasing viral load and risk of transmission (<xref ref-type="bibr" rid="B98">Salehi et&#x20;al., 2019b</xref>; <xref ref-type="bibr" rid="B105">Schneider et&#x20;al., 2019</xref>) Three antiviral drugs including acyclovir, valacyclovir and famciclovir are used that systemic medication is preferred and topical agents are not recommended. Like other STDs the best way for decreasing the prevalence of HSV is prevention.</p>
<p>Human immunodeficiency virus (HIV): is a retrovirus that invades the immune system and T&#x20;cells, causing decreased CD4 cells and immunity. (<xref ref-type="bibr" rid="B65">Klasse, 2012</xref>). HIV-1 and HIV-2 are two subtypes of HIV. HIV-1 is more aggressive and without treatment almost always caused AIDS (<xref ref-type="bibr" rid="B79">Melhuish and Lewthwaite, 2018</xref>). Early clinical manifestations of HIV infection occur approximately 4&#xa0;weeks after exposure and patients may have flu-like symptoms: fever, malaise, arthralgia, myalgia, rash, diarrhoea, pharyngitis and lymphadenopathy (<xref ref-type="bibr" rid="B79">Melhuish and Lewthwaite, 2018</xref>).</p>
<p>For HIV diagnosis, serological and virological tests are used; serological tests for HIV antibodies are the most important. If the screening test was positive or suspicious, a confirmatory test should be performed that includes virological tests for antigens, RNA, or an additional antibody test (western blot). The diagnosis of HIV is based on these positive confirmatory tests. (<xref ref-type="bibr" rid="B22">Centers for Disease Control Prevention, 2005</xref>). With the introduction of antiretroviral therapy (ART), the epidemiology of HIV has changed. Before ART, the prevalence and incidence and rate of HIV mortality were high; after ART use, the mortality rate and incidence decreased, but the prevalence increased due to the high life expectancy of these patients (<xref ref-type="bibr" rid="B54">HIV/AIDS J.U.N.P.O, 2017</xref>). Any strategies for effective prevention should contain structural, behavioural and medical approaches.</p>
<p>
<italic>Molluscum Contagiosum</italic> is a skin infection caused by a poxvirus member (genus Molluscipoxvirus) This infection affects both genders and can be transmitted to neonates from pregnant women (<xref ref-type="bibr" rid="B75">Luke and Silverberg, 2010</xref>) and is more common in children and transmitted by casual skin-skin contact and towel contact. This virus includes three subtypes, subtype one being the most common. Itching is the most common symptom, but patients can also be asymptomatic. The appearance of characteristic lesions is important for diagnosis, but in the case of atypical lesions or immunocompromised patients, the biopsy of the lesion should be done to rule out malignancy (<xref ref-type="bibr" rid="B120">Van Der Wouden et&#x20;al., 2017</xref>). In the biopsy specimen, Henderson-Patterson bodies or molluscum bodies are important for diagnosis (<xref ref-type="bibr" rid="B35">Eleftheriou et&#x20;al., 2011</xref>). The lesion may spread with shaving and scratching and a bacterial superimposed infection may occur (<xref ref-type="bibr" rid="B32">Desruelles et&#x20;al., 2013</xref>).</p>
<p>If people develop genital <italic>Molluscum contagiosum</italic>, other STDs should be evaluated in the patient (<xref ref-type="bibr" rid="B70">Leung et&#x20;al., 2017</xref>). These lesions are self-limited but it may take 0.5&#x2013;5&#xa0;years or longer in immunocompromised patients so treatment is recommended for increasing quality of life (<xref ref-type="bibr" rid="B81">Meza-Romero et&#x20;al., 2019</xref>). Traditional therapies are curettage and cryotherapy but these are painful (<xref ref-type="bibr" rid="B110">Simonart and De Maertelaer, 2008</xref>). Nowadays laser therapy is recommended (<xref ref-type="bibr" rid="B5">Binder et&#x20;al., 2008</xref>) also topical therapy with imiquimod, podophyllotoxin, and potassium hydroxide is used. Systemic therapy with cidofovir is useful only in immunocompromised patients.</p>
</sec>
</sec>
<sec id="s4">
<title>Potential Bioactive Compounds Against Sexually Transmitted Diseases Pathogens: Mechanisms and Molecular Targets</title>
<sec id="s4-1">
<title>Antibacterial Action</title>
<p>Several formulations of commonly used medicinal plant species have exhibited both <italic>in&#x20;vitro</italic> and <italic>in vivo</italic> anti-chlamydial activity (<xref ref-type="fig" rid="F2">Figure&#x20;2</xref>) (<xref ref-type="bibr" rid="B102">Salehi et&#x20;al., 2019c</xref>; <xref ref-type="bibr" rid="B103">Salehi et&#x20;al., 2019d</xref>), including activity in clinical studies, although the specific compounds and mechanisms of action have not yet is determined (<xref ref-type="bibr" rid="B93">Potroz and Cho, 2015</xref>; <xref ref-type="bibr" rid="B97">Salehi et&#x20;al., 2019a</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>
<bold>(A)</bold> Representation of the selected bioactive plant species <bold>(B)</bold> structures of the bioactive compounds against STDs caused by bacteria. Abbreviations and symbols: &#x2193;decrease, chlamydial protease-like activity factor (CPAF), regulatory factor X-5 (RFX5).</p>
</caption>
<graphic xlink:href="fphar-12-674682-g002.tif"/>
</fig>
<p>Polyphenols are natural compounds recognized for their antioxidant, anti-inflammatory, antibacterial, antitumor and anti-atherogenic action (<xref ref-type="bibr" rid="B108">Sharifi-Rad et&#x20;al., 2020</xref>; <xref ref-type="bibr" rid="B101">Salehi et&#x20;al., 2020</xref>). <xref ref-type="bibr" rid="B133">Yamazaki et&#x20;al. (2003)</xref> evaluated the effect of catechin-rich green polyphenol tea extract on <italic>C. trachomatis</italic>-infected human cells, where complete inhibition of <italic>C. trachomatis</italic> occurred from 1.6&#xa0;mg/ml for serovar D and 0.4&#xa0;mg/ml for the L2 strain. The polyphenol or Polyphenon 70S comprises epigallocatechin, epicatechin, epigallocatechin gallate, epicatechin gallate, and gallocatechin gallate (<xref ref-type="fig" rid="F2">Figure&#x20;2</xref>). Epigallocatechin gallate is the dominant constituent considered to be the major contributor to the observed antimicrobial effects. (<xref ref-type="bibr" rid="B133">Yamazaki et&#x20;al., 2003</xref>). All five&#x20;catechins showed an <italic>in&#x20;vitro</italic> inhibitory effect on the proliferation of <italic>C. trachomatis</italic>, and epicatechin was the least toxic (<xref ref-type="fig" rid="F2">Figure&#x20;2</xref>). Because the concentration of tea polyphenols required for complete inhibition of <italic>C. trachomatis</italic> is high compared to antibiotics, tea polyphenols are not currently suitable for the treatment of systemic infections. Modifying the structure of catechin may be the solution to reduce the required dose and its toxicity in topical microbicidal pharmaceutical&#x20;forms.</p>
<p>Another study conducted by <xref ref-type="bibr" rid="B51">Hao et&#x20;al. (2009)</xref> showed the flavonoid baicalin derived from <italic>Scutellaria</italic> radix at 0.12, 0.24, 0.48&#xa0;mg/ml concentrations presented an antibacterial activity against <italic>C. trachomatis</italic> at all tested concentrations. Western blot and RT-PCR assays showed the expression of RFX5 genes during the experiments where the stimulation of CPAF genes protein expression, representative downstream targets of the chlamydial protease-like activity factor (CPAF) in Hep-Cells 2 (Pb0.05). Baicalin presented significant results concerning CPAF protein expression attenuation. From these results, it can be concluded that baicalin can regulate the expression of CPAF and r<italic>egulatory</italic> factor X-5 (RFX5) (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Diagram with the most important molecular mechanisms and targets of natural bioactive compounds as potential alternative agents of STDs. Abbreviations and symbols: &#x2191;increased, &#x22A5; inhibition, chlamydial protease-like activity factor (CPAF), regulatory factor X-5 (RFX5), human immunodeficiency virus type 1 (HIV-1)<italic>.</italic>
</p>
</caption>
<graphic xlink:href="fphar-12-674682-g003.tif"/>
</fig>
<p>A recent study tested the chloroform extract from three plant species (<italic>Ocimum sanctum</italic> L., <italic>Drynaria quercifolia</italic> (L.) J.&#x20;Sm., and <italic>Annona squamosa</italic> L. for some of them see <xref ref-type="fig" rid="F2">Figure&#x20;2</xref>) for their activity against <italic>N. gonorrhoea</italic> with the disk diffusion method compared with penicillin and ciprofloxacin. Extracts from all three plants presented <italic>Neisseria</italic> growth inhibition at all concentrations (<xref ref-type="bibr" rid="B109">Shokeen et&#x20;al., 2005</xref>).</p>
</sec>
<sec id="s4-2">
<title>Antifungal Action</title>
<p>Based on ethnopharmacological data, 18 plants were tested against microorganisms associated with urogenital infections/STDs. The dichloromethane: methanol extracts and aqueous extracts presented effects against <italic>C. albicans</italic> (<xref ref-type="bibr" rid="B121">Van Vuuren and Naidoo, 2010</xref>). Fractions (50&#xa0;mg/ml) from 12 plant species were evaluated against <italic>C. albicans</italic>. The best minimum inhibitory concentration (MIC) results were obtained with the dichloromethane and ethanol extract from <italic>Bolusanthus speciosus</italic> (Bolus) Harms leaves (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>, <xref ref-type="table" rid="T2">Table&#x20;2</xref>), bark and stems (0.015&#x2013;0.193&#xa0;mg/ml), the ethanolic extracts from <italic>Ekebergia capensis</italic> Sparrm. leaves (0.39&#xa0;mg/ml), <italic>Pterocarpus angolensis</italic> DC., <italic>Pappea capensis</italic> Eckl. &#x26; Zeyh. (0.195&#xa0;mg/ml), <italic>Ximenia caffra</italic> Sond. (0.78&#xa0;mg/ml) and <italic>Osyris lanceolata</italic> Hochst. &#x26; Steud. roots (0.098&#xa0;mg/ml). The minimum fungicidal concentration obtained better results with <italic>B. speciosus</italic> (0.012&#xa0;mg/ml) (<xref ref-type="bibr" rid="B83">Mulaudzi et&#x20;al., 2011</xref>) (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Representation of the selected bioactive plant species against STDs caused by fungus.</p>
</caption>
<graphic xlink:href="fphar-12-674682-g004.tif"/>
</fig>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Pharmacological properties of selected plants/natural compounds against STDs pathogens.</p>
</caption>
<table>
<thead>
<tr>
<td align="left">Pharmacological activities</td>
<td align="center">Plant used/compounds</td>
<td align="center">Model</td>
<td align="center">Dose</td>
<td align="center">Major findings</td>
<td align="center">Refs.</td>
</tr>
</thead>
<tbody valign="top">
<tr>
<td colspan="6" align="left">
<italic>Antibacterial effects</italic>
</td>
</tr>
<tr>
<td rowspan="5" align="left">
<bold>Anti-chlamydia</bold>
</td>
<td align="left">Catechin-rich green polyphenol tea extract</td>
<td align="left">
<italic>C. trachomatis</italic>-infected human cells/<italic>in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 1.6&#xa0;mg/ml</td>
<td align="left">&#x2193; C. <italic>trachomatis</italic> proliferation</td>
<td align="left">
<xref ref-type="bibr" rid="B133">Yamazaki et&#x20;al. (2003)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Scutellaria</italic> radix/baicalein</td>
<td rowspan="2" align="left">Hep-2 cells infected by <italic>C. trachomatis/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 0.12, 0.24, 0.48&#xa0;g/ml</td>
<td align="left">&#x2191; RFX5</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B51">Hao et&#x20;al. (2009)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2193;CPAF</td>
</tr>
<tr>
<td align="left">
<italic>Ocimum sanctum</italic> L., <italic>Drynaria quercifolia</italic> L</td>
<td rowspan="2" align="left">
<italic>N. gonorrhoeae/</italic>disk diffusion method/<italic>in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 1,000&#xa0;&#x3bc;g/L</td>
<td rowspan="2" align="left">
<italic>&#x2193; N. gonorrhoeae</italic>
</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B109">Shokeen et&#x20;al. (2005)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Annona squamosa</italic> L./chloroform extract</td>
</tr>
<tr>
<td colspan="6" align="left">
<bold>
<italic>Antifungal effects</italic>
</bold>
</td>
</tr>
<tr>
<td rowspan="22" align="left">
<bold>Anti-candida</bold>
</td>
<td rowspan="10" align="center">18 plants/bark, stems, roots dichloromethane:methanol extracts and aqueous extracts</td>
<td rowspan="10" align="center">
<italic>C. albicans</italic>/<italic>in&#x20;vitro</italic>
</td>
<td align="left">
<italic>Bolusanthus</italic>&#xa0;<italic>speciosus</italic>
</td>
<td rowspan="10" align="left">Antifungal effect</td>
<td rowspan="10" align="center">
<xref ref-type="bibr" rid="B121">Van Vuuren and Naidoo (2010)</xref>
</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 0.015&#x2013;0.193&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">
<italic>Pterocarpus angolensis</italic> DC., <italic>Pappea capensis</italic> eckl. &#x26; zeyh</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 0.195&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">
<italic>Ximenia caffra</italic> sond</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 0.78&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">
<italic>Osyris lanceolata</italic> hochst. &#x26; steud</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 0.098&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">
<italic>B. speciosus</italic>
</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 0.012&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">
<italic>Sapindus mukorossi</italic> gaertn</td>
<td align="left">
<italic>C. albicans</italic>
</td>
<td rowspan="3" align="left">IC<sub>50</sub> &#x3d; 15&#xa0;mg/ml</td>
<td rowspan="3" align="left">Antifungal effect</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B116">Talwar et&#x20;al. (2000)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Mentha piperita</italic> L</td>
<td align="left">
<italic>C. tropicalis, C. krusei/in&#x20;vitro</italic>
</td>
</tr>
<tr>
<td align="left">
<italic>Azadirachta indica</italic> a</td>
<td align="left"/>
</tr>
<tr>
<td align="left">13 plant species/aqueous, ethanolic, ethyl acetate extracts</td>
<td align="left">
<italic>C. albicans/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 100&#xa0;mg/ml</td>
<td align="left">Antifungal effect</td>
<td align="left">
<xref ref-type="bibr" rid="B10">Buwa and van Staden (2006)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Aloe ferox</italic> mill</td>
<td align="left">
<italic>C. albicans/</italic>agar diffusion, microdilution</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 20&#xa0;mg/ml</td>
<td rowspan="2" align="left">Antifungal effect</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B61">Kambizi and Afolayan (2008)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Jatropha multifida</italic> L. stem and bark/hexane, methanolic, ethyl acetate extracts</td>
<td align="left">Methods/<italic>in&#x20;vitro</italic>
</td>
</tr>
<tr>
<td align="left">19 plant species/organic dichloromethane: Methanol extract, aqueous extracts</td>
<td align="left">
<italic>C. albicans/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.38&#x2013;16&#xa0;mg/ml</td>
<td align="left">Antifungal effect</td>
<td align="left">
<xref ref-type="bibr" rid="B58">Jadhav et&#x20;al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Acacia karroo</italic> Hayne/roots, <italic>Rhoicissus tridentata</italic> (L.f.) wild &#x26; R.B.Drumm/roots</td>
<td rowspan="3" align="left">
<italic>C. albicans/</italic>broth microdilution method/<italic>in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.8&#xa0;mg/ml</td>
<td rowspan="3" align="left">Antifungal effect</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B77">Mamba et&#x20;al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Cassine crocea</italic> (thunb) C.Presl/bark, <italic>Hilliardiella nudicaulis</italic> (DC.)</td>
<td align="left">IC<sub>50</sub> &#x3d; 1.6&#xa0;mg/ml</td>
</tr>
<tr>
<td align="left">H.Rob./whole plant</td>
<td align="left"/>
</tr>
<tr>
<td align="left">
<italic>P. capensis</italic>
</td>
<td align="left">
<italic>C. albicans/</italic>broth microdilution method/<italic>in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.39&#xa0;mg/ml - 6.25&#xa0;mg/ml</td>
<td align="left">Antifungal effect</td>
<td align="left">
<xref ref-type="bibr" rid="B91">Pendota et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Grewia flava</italic> DC., <italic>Jatropha zeyheri</italic> Sond./roots, <italic>Cassia abbrevia</italic> Oliv./leaves</td>
<td align="left">
<italic>C. albicans/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.20&#xa0;mg/ml</td>
<td align="left">Antifungal effect</td>
<td align="left">
<xref ref-type="bibr" rid="B82">Mongalo et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td colspan="6" align="left">
<bold>
<italic>Anti- parasites effects</italic>
</bold>
</td>
</tr>
<tr>
<td rowspan="16" align="left">
<bold>Anti- trichomonas</bold>
</td>
<td rowspan="2" align="left">
<italic>Manilkara rufula</italic> (miq.) H.J.Lam/leaves</td>
<td rowspan="2" align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 1.0&#xa0;mg/ml</td>
<td align="left">Anti-Trichomonas activity</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B30">de brum Vieira et&#x20;al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2193;trophozoites viability</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Nectandra megapotamica</italic> (spreng.)<italic>/bark, leaves/</italic>essential oil</td>
<td rowspan="2" align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 98.7&#xa0;&#x3bc;g/ml</td>
<td align="left">Anti-Trichomonas activity</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B39">Farias et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2193;trophozoites viability</td>
</tr>
<tr>
<td rowspan="3" align="left">
<italic>Pistacia lentiscus</italic> L.mastic, <italic>Ocimum basilicum</italic> L./oil</td>
<td rowspan="3" align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 15&#xa0;mg/ml</td>
<td align="left">100% trophozoites growth inhibition damage to the trophozoite membrane system</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B36">Ezz eldin and Badawy (2015)</xref>
</td>
</tr>
<tr>
<td align="left">IC<sub>50</sub> &#x3d; 30&#xa0;&#x3bc;g/ml</td>
<td align="left">&#x2191;abnormal cytoplasm vacuolization</td>
</tr>
<tr>
<td align="left"/>
<td align="left">&#x2191;cytoplasm destruction</td>
</tr>
<tr>
<td align="left">
<italic>Rheum ribes</italic> L./flower essential oil/aqueous extract from leaves, flower, stem</td>
<td align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.5&#xa0;mg/ml</td>
<td align="left">Anti-Trichomonas activity</td>
<td align="left">
<xref ref-type="bibr" rid="B85">Naemi et&#x20;al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Cassine xylocarpa</italic> vent. Leaves, bark, and roots</td>
<td align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.46&#xa0;&#x3bc;g/ml</td>
<td align="left">Anti-Trichomonas activity</td>
<td align="left">
<xref ref-type="bibr" rid="B96">Roca-M&#xe9;zquita et&#x20;al. (2016)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Verbena</italic> sp., <italic>C. xanthocarpa</italic>/aqueous extracts</td>
<td rowspan="2" align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 4.0&#xa0;mg/ml</td>
<td align="left">100% effect against the parasite</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B8">Brandelli et&#x20;al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Complete growth inhibition</td>
</tr>
<tr>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td rowspan="2" align="left">
<italic>Hypericum polyanthemum</italic> klotzsch ex reichardt/aqueous extracts</td>
<td rowspan="2" align="left">
<italic>T. vaginalis</italic> 30,236 (ATCC)<italic>/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 250&#xa0;&#x3bc;g/ml</td>
<td align="left">Anti-Trichomonas activity</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B17">Cargnin et&#x20;al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Killing 47% of trophozoites</td>
</tr>
<tr>
<td align="left">
<italic>Morinda panamensis</italic> seem roots/anthraquinone</td>
<td align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 1.03&#xa0;&#x3bc;g/ml</td>
<td align="left">Satisfactory activity against <italic>T. vaginalis</italic>
</td>
<td align="left">
<xref ref-type="bibr" rid="B11">C&#xe1;ceres-Castillo et&#x20;al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Sapindus/</italic>saponins</td>
<td align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td align="left">Concentration 0,0005%</td>
<td align="left">&#x2193; viability &#x2193;<italic>Trichomonas</italic> trophozoite numbers</td>
<td align="left">
<xref ref-type="bibr" rid="B118">Tiwari et&#x20;al. (2008)</xref>
</td>
</tr>
<tr>
<td rowspan="2" align="left"/>
<td align="left">
<italic>Verbascum thapsus</italic> L</td>
<td rowspan="2" align="left">
<italic>T. vaginalis/in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 800&#xa0;&#x3bc;g/ml</td>
<td rowspan="2" align="left">&#x2191;apoptosis in trophozoites</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B37">Fakhrieh-Kashan et&#x20;al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Zingiber officinale</italic> roscoe</td>
</tr>
<tr>
<td colspan="6" align="left">
<bold>
<italic>Antiviral effect</italic>
</bold>
</td>
</tr>
<tr>
<td rowspan="6" align="left">
<bold>anti-HIV-1 activity</bold>
</td>
<td rowspan="2" align="left">
<italic>Myrothamnus flabellifolia</italic> welw./3,4,5-tri-<italic>O</italic>-galloylquinic acid</td>
<td rowspan="2" align="left">M-MLV RT/<italic>in&#x20;vitro</italic>
</td>
<td rowspan="2" align="left">IC<sub>50</sub> &#x3d; 82&#xa0;&#x3bc;M</td>
<td align="left">&#x2193;HIV-1</td>
<td rowspan="2" align="left">
<xref ref-type="bibr" rid="B62">Kamng&#x2019;ona et&#x20;al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left">&#x2193;RT</td>
</tr>
<tr>
<td rowspan="3" align="left">
<italic>Calophyllum brasiliense</italic> cambess/hexanic, acetonic, methanolic extracts</td>
<td align="left">MT2 human lymphocytes</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.34&#xa0;&#x3bc;M/ml</td>
<td align="left">&#x2193;HIV-1</td>
<td rowspan="3" align="left">
<xref ref-type="bibr" rid="B56">Huerta-Reyes et&#x20;al. (2004a)</xref>
</td>
</tr>
<tr>
<td align="left">HIV-I RT/<italic>in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3d; 0.5&#xa0;&#x3bc;M/ml</td>
<td align="left">&#x2193;RT</td>
</tr>
<tr>
<td align="left"/>
<td align="left">IC<sub>50</sub> &#x3d; 0.66&#xa0;&#x3bc;M/ml</td>
<td align="left">&#x2193;HIV-1 IIIb/LAV &#x2193;replication</td>
</tr>
<tr>
<td align="left">
<italic>Ferula moschata</italic> (H.Reinsch) koso-pol./dry root methanolic extract</td>
<td align="left">H9 lymphocytes/<italic>in&#x20;vitro</italic>
</td>
<td align="left">IC<sub>50</sub> &#x3e; 100&#xa0;mg/ml</td>
<td align="left">&#x2193;HIV replication</td>
<td align="left">
<xref ref-type="bibr" rid="B136">Zhou et&#x20;al. (2000)</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Abbreviations and symbols: &#x2191; increased, &#x2193; decreased, chlamydial protease-like activity factor (CPAF), human immunodeficiency virus type 1 (HIV-1), lymphadenopathy-associated virus (LAV), reverse transcriptase (RT), regulatory factor X-5 (RFX5).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The antifungal effect of two medicinal cream formulations (50%) produced from <italic>Sapindus mukorossi</italic> Gaertn., <italic>Mentha &#xd7; piperita</italic> L. and <italic>Azadirachta indica</italic> A. Juss herbs have been evaluated to validate their popular use in the treatment of STDs. The formulations presented inhibition halos ranging from 11 to 17&#xa0;mm against <italic>C. albicans</italic>, <italic>Candida tropicalis</italic>, and <italic>Candida krusei</italic>, compared to fluconazole (15&#xa0;mg/ml) with halos between 25 and 30&#xa0;mm (<xref ref-type="bibr" rid="B116">Talwar et&#x20;al., 2000</xref>).</p>
<p>About analysis with extracts, the aqueous, ethanolic, and ethyl acetate extracts (100&#xa0;mg/ml) from 13 plant species used to treat venereal diseases in Africa were evaluated. The best results with the broth microdilution method against <italic>C. albicans</italic> were obtained with the <italic>Bersama lucens</italic> (Hochst.) Szyszy&#x142;. bark extract (ethanolic: 0.78&#xa0;mg/ml) and the <italic>Harpephyllum caffrum</italic> Bernh. bark extracts (aqueous: 1.56&#xa0;mg/ml; ethanolic: 0.78&#xa0;mg/ml) compared to amphotericin B (0.195&#xa0;mg/ml). The results showed an inhibitory effect on these extracts (<xref ref-type="bibr" rid="B10">Buwa and van Staden, 2006</xref>).</p>
<p>In another study, <xref ref-type="bibr" rid="B61">Kambizi and Afolayan (2008)</xref> obtained <italic>C. albicans</italic> growth inhibition with the <italic>Aloe ferox</italic> Mill (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>). methanolic leaf extract (20&#xa0;mg/ml) by the agar diffusion method. The hexane, methanolic and ethyl acetate extracts (20&#xa0;mg/ml) from the <italic>Jatropha multifida</italic> L. stem and bark (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>) were evaluated by agar diffusion and microdilution methods by <xref ref-type="bibr" rid="B1">Aiyelaagbe et&#x20;al. (2008)</xref>, where the extracts presented inhibition halos ranging from 11 to 18&#xa0;mm against <italic>C. albicans</italic>, compared to 20&#xa0;mm with the Tioconazole.</p>
<p>
<xref ref-type="bibr" rid="B134">Zairi et&#x20;al. (2008)</xref> evaluated the antifungal action of dermaseptin-DS4 (peptide derived from frog skin) and its derivatives by microdilution against <italic>C. albicans</italic>. The inhibition against the fungus is dose-dependent inhibiting up to 90% of the population as the concentration was increased.</p>
<p>
<xref ref-type="bibr" rid="B86">Naidoo et&#x20;al. (2013)</xref> tested the effects of the organic dichloromethane: methanol extract and the aqueous extract from 19 plant species against <italic>C. albicans</italic>, finding that 11 species presented a potential with the aqueous extract (0.38&#x2013;16&#xa0;mg/ml), with <italic>Syzygium cordatum</italic> Hochst. ex Krauss and <italic>Tabernaemontana elegans</italic> Stapf standing out. A total of 16 species presented anti-<italic>Candida</italic> activity (0.5&#x2013;16&#xa0;mg/ml), with the best effect produced by <italic>S. cordatum</italic>. Amphotericin B was active at 2.5&#xa0;&#x3bc;g/ml. The methanolic extract and ethyl acetate fraction (10&#xa0;mg/ml) extracted from <italic>Terminalia crenulata</italic> Roth. fruits showed antifungal action against <italic>C. albicans</italic> with the agar diffusion method. Inhibition halos ranged from 10 to 15&#xa0;mm for the extracts and from 36 to 33&#xa0;mm for fluconazole (25&#xa0;&#xb5;g/disc) (<xref ref-type="bibr" rid="B58">Jadhav et&#x20;al., 2015</xref>).</p>
<p>
<xref ref-type="bibr" rid="B77">Mamba et&#x20;al. (2016)</xref> observed the antifungal effect of the ethanolic extracts from <italic>Acacia karroo</italic> Hayne (roots), <italic>Rhoicissus tridentata</italic> (L.f.) Wild &#x26; R.B.Drumm. (roots), with MICs of 0.8&#xa0;mg/ml, and <italic>Senna</italic> italic Mill. (roots), <italic>Cassine crocea</italic> (Thunb.) C. Presl (bark) and <italic>Hilliardiella nudicaulis</italic> (DC.) H. Rob. (whole plant), with MICs of 1.6&#xa0;mg/ml against <italic>C. albicans</italic> with the broth microdilution method more than Ciprofloxacin. The methanolic extract from <italic>Pappea capensis</italic> (100&#xa0;mg/ml) and the solvent fractions was tested <italic>against C. albicans</italic> by the broth microdilution method, where MIC values ranged from 0.39&#xa0;mg/ml to 6.25&#xa0;mg/ml more than amphotericin B (<xref ref-type="bibr" rid="B91">Pendota et&#x20;al., 2017</xref>).</p>
<p>In a South African study, acetone extracts from <italic>Grewia flava</italic> DC. and <italic>Jatropha zeyheri</italic> Sond. roots, as well as <italic>Cassia abbrevia</italic> Oliv. leaves inhibited <italic>C. albicans</italic> growth with a MIC of 0.20&#xa0;mg/ml. Aqueous extracts from <italic>G. flava</italic> and <italic>Waltheria indica</italic> L. were associated and also presented an effect against <italic>C. albicans.</italic> The amphotericin B control presented an effect at deficient concentrations compared to the extracts (<xref ref-type="bibr" rid="B82">Mongalo et&#x20;al., 2017</xref>).</p>
<p>
<xref ref-type="bibr" rid="B106">Seleteng-Kose et&#x20;al. (2019)</xref> evaluated 20 plants against <italic>C. albicans</italic> using their aqueous and organic (dichloromethane: methanol) extracts (leaf and stem roots). Only four plant species, <italic>Bulbine narcissifolia</italic> Salm-Dyck roots (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>) (aqueous and organic extracts), <italic>Helichrysum caespititium</italic> (DC.) Sond. ex Harv. (organic extract), <italic>Phygelius capensis</italic> E. Mey. ex Benth. (aqueous extract) and <italic>Rhamnus prinoides</italic> L&#x27;H&#xe9;r. leaf (organic extract), presented antifungal activity.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Selected bioactive compounds against STDs caused by parasites, specifically by protozoa.</p>
</caption>
<graphic xlink:href="fphar-12-674682-g005.tif"/>
</fig>
</sec>
<sec id="s4-3">
<title>Anti-Parasites Action</title>
<p>In a study conducted by <xref ref-type="bibr" rid="B30">de brum Vieira et&#x20;al. (2017)</xref> evaluated the anti-<italic>T. vaginalis</italic> activity of 7 fractions from <italic>Manilkara rufula</italic> (Miq.) H.J.Lam leaves extracted with acetone and analyze by LC-DAD-MS/MS (liquid chromatography-diode array detector-tandem mass spectrometry), MALDI-MS (matrix-assisted laser desorption/ionization-mass spectrometry), and MALDI-MS/MS. The anti-trichomonas activity and MIC were tested with a 1.0&#xa0;mg/ml concentration from the fractions or standard compounds (100&#xa0;mM). The crude fractions reduced <italic>T. vaginalis</italic> viability by over 90%, while all the fractions obtained from ML-A10 reduced trophozoites viability by more than 80%, except the M50 fraction. The M30 and M100 fractions at concentrations from 2.0 to 0.0156&#xa0;mg/ml were used for the MIC determination. However, none of these concentrations was able to eliminate <italic>T. vaginalis</italic> cellular viability. The M30 fraction consists mainly of flavanols and flavan-3-of derivatives, while the M100 fraction consisted of mainly gallic acid, flavan-3-ol, and flavonols. The author also points out that this is the first time the anti-trichomonas activity of the tannins in question is described. In addition to the anti-<italic>T. vaginalis</italic> activity of the condensed tannins from the M100&#x20;<italic>M. rufula</italic> fraction, the author also reports its action against <italic>Tritrichomonas foetus</italic>, thus demonstrating new manners for anti-trichomonas treatment.</p>
<p>
<xref ref-type="bibr" rid="B39">Farias et&#x20;al. (2019)</xref> evaluated the essential oil of several species from the genus <italic>Nectandra</italic>. They tested their activity against <italic>T. vaginalis</italic>, in addition to evaluating their antibacterial and biofilm inhibiting effects. The oils were extracted from both the bark and leaves by steam distillation and analyzed by gas chromatography (GC)-MS, with concentrations from 7.8 to 1,000&#xa0;&#x3bc;g/ml being used for the anti-<italic>T. vaginalis</italic> activity evaluation. The action of the <italic>Nectandra megapotamica</italic> (Spreng.) Mez essential oil was evaluated <italic>in&#x20;vitro</italic> presented activity against <italic>T. vaginalis</italic> with an IC<sub>50</sub> of 98.7&#xa0;&#x3bc;g/ml. The viability of the trophozoites was 1.10&#x20;&#xb1; 0.69 at the 250&#xa0;&#x3bc;g/ml concentration and zeroed at 500&#xa0;&#x3bc;g/ml. The author points out that these are promising results and that &#x3b1;-pinene, &#x3b2;-pinene, and limonene are found in this&#x20;oil.</p>
<p>
<xref ref-type="bibr" rid="B36">Ezz eldin and Badawy (2015)</xref> analyzed the <italic>in&#x20;vitro</italic> effects of <italic>Pistacia lentiscus</italic> L. and <italic>Ocimum basilicum</italic> L. oil against <italic>T. vaginalis</italic> trophozoites. The cultures treated with <italic>P. lentiscus</italic> showed varying degrees of growth inhibition at different time points. However, 100% growth inhibition was observed at a concentration of 15&#xa0;mg/ml after 24&#xa0;h of incubation. In cultures treated with <italic>O. basilicum</italic> oil, an inhibition of 100% parasitic growth was observed at a concentration of 30&#xa0;&#x3bc;g/ml after 24&#xa0;h of incubation. There was also a 73.1% decrease in trophozoite growth at a concentration of 20&#xa0;&#x3bc;g/ml after 24&#xa0;h and complete inhibition of their growth after 48&#xa0;h. Regarding the transmission electron microscopy (TEM) test, it was shown that both plants cause considerable damage to the cell membranes of trophozoites with abnormal cytoplasm vacuolation, extensive destruction of the cytoplasm, apoptosis with cell death of trophozoites. The author points out the anti - <italic>T. vaginalis</italic> activity of <italic>P. lentiscus</italic> may be attributed to its ability to induce apoptosis and that of <italic>O. basilicum</italic> to active saponin and flavonoid contents found in the oil (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<p>
<xref ref-type="bibr" rid="B122">Vazini (2017)</xref> evaluated the anti-trichomonas activity of nanoemulsions made from <italic>Mikania cordifolia</italic> (L.f.) Willd<italic>.</italic>. For the test, the drug MTZ was used as a positive control. The <italic>M. cordifolia</italic> nanoemulsion at the 500&#xa0;ppm concentration is capable of eliminating 85% of trophozoites at 72&#xa0;h.</p>
<p>
<xref ref-type="bibr" rid="B85">Naemi et&#x20;al. (2014)</xref> used the <italic>Rheum ribes</italic> L. flower essential oil in their study, GC-MS analyzed that, and the organic and aqueous extract from the leaves, flower, and stem as well as the 11 fractions obtained. After that, the extracts and fractions were mixed with the parasite. MTZ was used as the control. All fractions presented higher activity at 48&#xa0;h compared to 24&#xa0;h. The <italic>R. ribes</italic> flower water fraction presented the highest growth inhibition percentage with the lowest concentration (0.5&#xa0;mg/ml) after 24&#xa0;h compared to the positive. The author reports that, according to the results, the aqueous <italic>R. ribes</italic> flower extract may be used for the drug development of anti-trichomoniases&#x20;drugs.</p>
<p>The dichloromethane and methanol extract from <italic>Cassine xylocarpa</italic> Vent. leaves, bark, and roots were used to evaluate the plant&#x2019;s activity against several microorganisms, including <italic>T. vaginalis</italic>. The solutions were inoculated with <italic>T. vaginalis</italic> trophozoites followed by incubation, MTZ was used as control. The root bark dichloromethane extract presented an IC<sub>50</sub> of 0.46&#xa0;&#x3bc;g/ml against the parasite. The author reports this was the first the extracts as mentioned above were tested; however, only the root bark dichloromethane extract presented activity (<xref ref-type="bibr" rid="B96">Roca-M&#xe9;zquita et&#x20;al., 2016</xref>).</p>
<p>Ten plants traditionally used by indigenous cultures were tested for their <italic>in&#x20;vitro</italic> anti-<italic>T. vaginalis</italic> activity including <italic>Aloe arborescens</italic> Mill. leaves, <italic>Bidens pilosa</italic> L. aerial parts, <italic>Rhipsalis baccifera</italic> (J.S.Muell.) Stearn aerial parts, <italic>Luehea divaricata</italic> Mart. barks, <italic>Trichilia</italic> sp. roots, <italic>Campomanesia xanthocarpa</italic> (Mart.) O. Berg leaves, <italic>Coix lacryma-jobi</italic> L. leaves., <italic>Citrus limon</italic> (L.) Osbeck leaves, <italic>Citrus reticulata</italic> Blanco leaves and <italic>Verbena</italic> sp. leaves. From the tested extracts, the <italic>Verbena</italic> sp. and <italic>C. xanthocarpa</italic> aqueous extracts presented the highest activity against <italic>T. vaginalis</italic> with MIC values of 4.0&#xa0;mg/ml, with <italic>Verbena</italic> sp. presenting 100% effect against the parasite and <italic>C. xanthocarpa</italic> up to 96% against all isolates. MTZ was used as the control. Kinetic growth assays showed the extracts promoted complete growth inhibition after 4&#xa0;h of incubation (<xref ref-type="bibr" rid="B8">Brandelli et&#x20;al., 2013</xref>).</p>
<p>
<xref ref-type="bibr" rid="B17">Cargnin et&#x20;al. (2013)</xref> evaluated the activity of the <italic>Hypericum polyanthemum</italic> Klotzsch ex Reichardt extract and the chemical compounds isolated and purified from it (benzopyrans HP1, HP2, HP3, and the phloroglucinol derivative uliginosin B) against <italic>T. vaginalis</italic> trophozoites. Two <italic>T. vaginalis</italic> isolates were used in the assay, 30,236 (ATCC), which is sensitive to MTZ and the MTZ-resistant isolate TV-LACM2. The following were used for the controls: 8.0&#xa0;&#x3bc;M MTZ for the sensitive <italic>T. vaginalis</italic> isolate (30,236) and 289&#xa0;&#x3bc;M MTZ for the resistant isolate (TV -LACM2). The antiprotozoal activity of all isolated compounds was dose-dependent, with the phloroglucinol derivative being the most active. The benzopyran HP1 obtained a selective index value of 73.95, proving to be the most promising compound with significant antiprotozoal activity and selectivity. HP1 presented activity against a resistant clinical isolate (TV-LACM2), killing 47% of trophozoites at the highest concentration (250&#xa0;&#x3bc;g/ml). Additionally, HP1 with 8.0&#xa0;&#x3bc;M of MTZ showed a synergistic effect, improved the action of&#x20;MTZ.</p>
<p>An anthraquinone derived from <italic>Morinda panamensis</italic> Seem. roots were isolated and purified, having its action against <italic>T. vaginalis</italic> evaluated. MTZ 6.0&#xa0;&#x3bc;M was used as the control. The lucidin-&#x3c9;-isopropyl ether (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>) activity was examined in axenic trophozoites by IC<sub>50</sub>. Following 24&#xa0;h of exposure, the substance presented a satisfactory activity against <italic>T. vaginalis</italic> when incubated with varying concentrations (0&#x2013;20&#xa0;&#x3bc;g/ml). The inhibition (&#x223c;91%) observed with the 20&#xa0;&#x3bc;g/ml lucidin-&#x3c9;-isopropyl ether concentration was comparable to the inhibition (&#x223c;95%) observed after treatment with the control. The author reports that although anthraquinone presented anti-<italic>T. vaginalis</italic> activity, additional mode of action studies is needed to elucidate the antitrichomonal mechanism of action. (<xref ref-type="bibr" rid="B11">C&#xe1;ceres-Castillo et&#x20;al., 2019</xref>).</p>
<p>
<xref ref-type="bibr" rid="B118">Tiwari et&#x20;al. (2008)</xref> evaluated the anti-<italic>T. vaginalis</italic> activity of <italic>Sapindus</italic> saponins, a component of the plant-based contraceptive Consap, where the <italic>Sapindus</italic> saponins purified sample and MTZ was used. <italic>T. vaginalis</italic> susceptibility was tested being incubated in the presence of serially diluted MTZ (1&#x2013;12&#xa0;mM) and <italic>Sapindus</italic> saponins. No growth was observed after 24 and 48&#xa0;h of incubation at 0.005% saponin concentration. <italic>Sapindus</italic> saponins reduced viability and <italic>Trichomonas</italic> trophozoite numbers at 0.001 and 0.0025% concentrations without live parasites being observed at the 0.005% saponin concentration (MIC) at 12&#xa0;h.</p>
<p>
<xref ref-type="bibr" rid="B41">Frasson et&#x20;al. (2012)</xref> tested 23 different plant species against <italic>T. vaginalis</italic> isolates, including (ATCC) 30,236 and 30,238, and four fresh clinical isolates, TV-LACH1, TV-LACH2, TV-LACM1 and TV- LACM2, where the activity of 44 aqueous extracts from <italic>Caatinga</italic> plants was screened against <italic>T. vaginalis</italic> trophozoites (ATCC 30236). Only the extract that reduced parasite viability by at least 50%, in this case, the aqueous extract, was used in the next experiments. Species belonging to the Polygalaceae family were&#x20;effective at significantly reducing trophozoite viability, where the <italic>Polygala decumbens</italic> A.W. Benn. root aqueous extract abolished trophozoite viability. The extract was capable of completely impairing parasite growth after the first hours of incubation.</p>
<p>Several substances were evaluated to analyze their anti-<italic>T. vaginalis</italic> activity, including caffeic acid, chlorogenic acid, &#x3b1;-chaconine, solanidine &#x3b1;-solanine and quercetin from frozen potato skin preparations. Parasite growth inhibition by the potato skin compounds was screened against the <italic>T. vaginalis</italic> G3 strain for growth inhibition. The &#x3b1;-solanine inhibitory activity was several times greater than &#x3b1;-chaconine. Potato phenolic compounds also inhibited the growth of the aforementioned strain however, inhibition was much smaller compared to the two glycoalcaldes described above. The potato skin inhibitory activity demonstrated that all skins were active in the assay. The potato samples with the highest activity were the thickest skin varieties and thin skin peels. The study showed the glycoalkaloid potato &#x3b1;-chaconine and &#x3b1;-solanine, the phenolic potato compound chlorogenic acid, caffeic acid and quercetin (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>), as well as potato skins prepared from commercial potatoes, presented antiprotozoal activity against pathogenic <italic>Trichomonas</italic> strains that infect humans, where two Russet samples were the most active (<xref ref-type="bibr" rid="B42">Friedman et&#x20;al., 2018</xref>).</p>
<p>
<italic>Verbascum thapsus</italic> L. and <italic>Zingiber officinale</italic> Roscoe plant extracts were analyzed concerning their action against <italic>T. vaginalis</italic>. Trophozoites were cultured with different concentrations of the <italic>V. thapsus</italic> and <italic>Z. officinale</italic> ethanolic extracts and MTZ combinations (concentrations from 25 to 800&#xa0;&#x3bc;g/ml at 12, 24 and 48&#xa0;h). The toxicity of the <italic>V. thapsus</italic> and <italic>Z. officinale</italic> ethanolic extract combination at the highest concentration (800&#xa0;&#x3bc;g/ml) at 48&#xa0;h was observed to be 1.98% in macrophage cells. At some concentrations the induction of apoptosis in trophozoites was observed (<xref ref-type="bibr" rid="B37">Fakhrieh-Kashan et&#x20;al., 2018</xref>) (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<p>A systematic review published <xref ref-type="bibr" rid="B137">Ziaei Hezarjaribi et&#x20;al. (2019)</xref> by of several plants that possess anti-<italic>T. vaginalis</italic> activity indicated that <italic>Mentha longifolia</italic> (L.) L. is one of the most effective medicinal plants against <italic>T. vaginalis</italic> (31). Additionally, <italic>Eucalyptus camaldulensis</italic> Dehn. presented significant inhibitory effects against <italic>T. vaginalis</italic> and may be used as a safer and more effective alternative to chemical agents for the treatment of this infection in the future.</p>
</sec>
<sec id="s4-4">
<title>Anti-Viral Effects</title>
<p>
<xref ref-type="bibr" rid="B48">Gokalp (2018)</xref> evaluated the inhibition of some garlic-derived compounds on HIV-1 as well as its action on the most commonly used drug (saquinavir) to treat the disease. Garlic derivatives that inhibit HIV-1 activity are, in ascending order, glutamyl cysteine &#x3e; ajoene &#x3e; diallyl trisulfide (DATS)&#x3e;allin &#x3e; s-allyl cysteine &#x3e; dially disulfide &#x3e; allicin &#x3e; diallyl sulfide (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>, <xref ref-type="table" rid="T2">Table&#x20;2</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Bioactive compounds against human immunodeficiency virus type 1 (HIV-1)&#x20;virus.</p>
</caption>
<graphic xlink:href="fphar-12-674682-g006.tif"/>
</fig>
<p>As for the garlic compound combined with the drug inhibitory activity order, glutamyl cysteine &#x3e; ajoene &#x3e; DATS &#x3e; allin &#x3e; s-allyl cysteine &#x3e; allicin &#x3e; dially disulfide &#x3e; diallyl sulfide were found to be in ascending order. The author also reports the importance of the anti-HIV-1 activity of garlic compounds, especially ajoene, however, also draws attention to the interaction between these compounds and the saquinavir&#x20;drug.</p>
<p>
<xref ref-type="bibr" rid="B62">Kamng&#x27;ona et&#x20;al. (2011)</xref> fractionated the polyphenol-rich extract from the <italic>Myrothamnus flabellifolia</italic> Welw. resurrection plant and isolated the most effective inhibiting fraction in his study. The compound 3,4,5-tri-<italic>O</italic>-galloylquinic acid was identified and analyzed to see if it inhibited the HIV-1 virus Reverse transcriptase (RT) enzyme, where the compound used in the study was extracted from dried <italic>M. flabellifolia</italic> leaves. The HIV-1 RT inhibitory activity of the polyphenol-rich extract and the inhibition kinetics of the 3,4,5-tri-O-galloylquinic acid compound was also evaluated. The results showed an exponential response of HIV-1 RT inhibition over a concentration range of up to 82&#xa0;&#x3bc;M with an estimated IC<sub>50</sub> of 34&#xa0;&#x3bc;M. The effect of nevirapine (drug) on HIV-1 RT activity was also analyzed. The results showed the addition of nevirapine to the 1&#xa0;mM RT assay caused twice the inhibition observed, however, the highest concentration was insufficient to reduce RT activity by 50%. Thus, the results obtained suggest that 3,4,5-tri-O-galloylquinic acid and its associated compounds may be useful as components of natural antiviral therapy.</p>
<p>The HIV-I RT <italic>in&#x20;vitro</italic> inhibitory capacity of 21 species from the Clusiaceae family was analyzed, as well as its toxicity in human lymphocytes and inhibition of HIV-1 replication.</p>
<p>For the <italic>Calophyllum brasiliense</italic> Cambess. species organic extracts were also prepared. The antiviral activity assay was performed in three steps, with first the inhibition of HIV-I RT being evaluated and those showing inhibition greater than 70% were used in the next assay addressing cytotoxicity in human cells and the extracts considered as non-toxic were used to determine HIV-1 IIIb/LAV replication inhibition. The drug nevirapine was used as a positive control. Five species (23.8%) showed a high anti-HIV-1 RT (&#x2265;70% inhibition) activity, while 7 species (33.3%) were moderately active (50&#x2013;70% inhibition) and 9 species showed less than 50% inhibition, where the most active extracts were from the same species, <italic>C. brasiliense</italic>. <italic>Clusia massoniana</italic> Lundell and <italic>Vismia baccifera</italic> (L.) Planch. &#x26; Triana extracts presented a 72.9% enzyme inhibition<italic>,</italic> while <italic>Clusia guatemalensis</italic> Hemsl. and <italic>Vismia camparaguey</italic> Sprague &#x26; L. Riley showed 70.8% inhibition. The toxicity assay was performed with 9 extracts and from these only 5 did not show toxicity: <italic>C. brasiliense</italic> (hexane, methanol and diclorometahne-methanol), <italic>V. baccifera</italic> and <italic>Clusia quadrangula</italic> Bartlett. For evaluation of the HIV-1 IIIb/LAV replication inhibition, the <italic>C. brasiliense</italic> hexane extract inhibited HIV-1 IIIb/LAV replication by 74.5%, while the methanol extract <italic>C. brasiliense</italic>, <italic>V. baccifera</italic> and <italic>C. quadrangula</italic> extracts exhibited less than 52% inhibition. The data obtained in this study suggests the <italic>C. brasiliense</italic> hexane extract possesses anti-HIV activities. Recently the authors identified the existence of 2&#xb0;<italic>C. brasiliense</italic> chemotypes in Mexico. The first one is included in this study and presented a high inhibitory value for the hexane, acetone and methanol extracts in the HIV-1 RT assay, suggesting these may possess HIV-1 inhibitory substances (<xref ref-type="bibr" rid="B57">Huerta-Reyes et&#x20;al., 2004b</xref>). Using the same previously reported methodology, the authors fractionated and evaluated the hexanoic, acetonic and methanolic extracts from <italic>C. brasiliense</italic> leaves, where the plant extracts were dried at room temperature. Most of the fractions obtained from the <italic>C. brasiliense</italic> hexane leaf extract presented low HIV-1 RT inhibition, however, fractions 18 and 19 showed high inhibition (over 70%) with these fractions also not showing toxicity to MT2 human lymphocytes as well as strongly inhibiting IIIb/LAV replication. Compounds 6 (IC<sub>50</sub> 0.34&#xa0;&#x3bc;M/ml), 7 (IC<sub>50</sub> 0.5&#xa0;&#x3bc;M/ml) and 9 (IC<sub>50</sub> 0.66&#xa0;&#x3bc;M/ml) showed potent HIV-1 RT inhibition, while compounds 4 and 5 exhibited low inhibition. Compounds 1 and 2 were also isolated from the hexane extract, however neither of these inhibited HIV-1 RT. As for the acetone fractions, fractions 1, 2 and 3 were evaluated for HIV-1 RT inhibition however, only fraction 2 presented a moderate activity where this fraction, which was analyzed by thin-layer chromatography (TLC), was suggested to contain cardenolides traces. Moreover, the methanol extract showed high HIV-1 RT inhibitory activity (83.3%), however, this value decreased to 38.6% after tannin removal. The ethyl acetate insoluble fraction from the methanol extract inhibited HIV-1 RT activity and presented low cytotoxicity, nevertheless, it was unable to inhibit IIIb/LAV replication. The <italic>C. brasiliense</italic> methanolic leaf extract showed inhibition of HIV-1 RT which may be attributed to the tannins present in the sample (<xref ref-type="bibr" rid="B56">Huerta-Reyes et&#x20;al., 2004a</xref>) (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>).</p>
<p>In another study by <xref ref-type="bibr" rid="B136">Zhou et&#x20;al. (2000)</xref>, isolation and characterization of eight new coumarins from <italic>Ferula moschata</italic> (H.Reinsch) Koso-Pol. the dry root methanolic extract and 19 other known coumarins were evaluated, as well as the anti-HIV activity and the inhibition of cytokine release of the extract. The author reports in his study that <italic>F. moschata</italic> is a rich source of coumarin derivatives. Compound 19 showed anti-HIV activity in that it inhibited HIV replication in H9 lymphocytes with EC50 values &#x3c;0.10&#xa0;mg/ml, in addition to inhibiting the growth of uninfected H9 cells with IC50 values &#x3e; 100&#xa0;mg/ml and a calculated therapeutic index (TI) &#x3e; 1,000. In general, a TI &#x3e; 5: 0 is considered to denote significant activity; compounds 11, 12, 13, 17 and 21 showed strong anti-HIV activity with TI values higher than&#x20;5.</p>
</sec>
</sec>
<sec id="s5">
<title>Clinical Studies</title>
<p>In a clinical study with 100 women, were randomly assigned to treatment with a Brazilian Peppertree (<italic>Schinus terebinthifolius</italic> Raddi-see <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>) gel and with placebo. The results showed a cure rate of 84% in patients with symptomatic bacterial vaginosis treated with the Brazilian Peppertree gel, revealing a statistically significant difference compared to the cure rate found among patients receiving placebo (47.8%). The results, therefore, suggest the Brazilian Peppertree gel may be a safe and effective therapeutic alternative for bacterial vaginosis (<xref ref-type="bibr" rid="B2">Amorim and Santos, 2003</xref>). In another clinical study, 34 traditional Bapedi healers from the Limpopo Province in South Africa reported treatments for STDs during interviews, where <italic>chlamydia</italic> was one of the four common conditions stated. In terms of <italic>chlamydia</italic> treatment, eight plant species were identified: <italic>Aloe marlothii</italic> subsp. <italic>marlothii</italic>, <italic>Eucomis pallidiflora</italic> subsp. <italic>pole-evansii</italic>, <italic>Gethyllis Namaquensis</italic> (Schonland) Oberm., <italic>Hypoxis obtusa</italic> Burch. ex Ker Gawl., <italic>Kleinia longiflora</italic> DC., <italic>Protea caffra</italic> subsp. <italic>caffra</italic>, <italic>Tribulus terrestris</italic> L. and <italic>Ziziphus mucronata</italic> Willd (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>).</p>
<p>In a recently conducted clinical study with female patients who had vaginal trichomoniasis resistant to MTZ drugs it was found that patients who were also resistant to the MTZ and tinidazole combination received treatment with <italic>Commiphora molmol</italic> (Engl.) Engl. ex Tschirch, In a recently conducted clinical study with female patients who had trichomoniasis resistant to MTZ, MTZ and tinidazole combination, these received treatment with <italic>Commiphora molmol</italic> (Engl.) Engl. ex Tschirch. In addition, the <italic>in&#x20;vitro</italic> effect against <italic>T. vaginalis</italic> of the <italic>Punica granatum</italic> L. pomegranate extract has been evaluated. The oil-resin myrrh-derived extract, <italic>C. molmol</italic> was administered to females resistant to MTZ and tinidazole in the form of two capsules (600&#xa0;mg) six to eight days, 2&#xa0;h before breakfast. All patients were seen immediately after completion of treatment and again 4&#x2013;6&#xa0;weeks later. In total, 33 cases were studied; 50% of patients (9/18) who received concomitant oral tinidazole were cured, but the cure rate was higher (73%) in patients (11/15) treated with a combination of oral MTZ and vaginal tinidazole.</p>
<p>At a pH of 4.65, <italic>P. granatum</italic> was effective against <italic>T. vaginalis</italic>, which was destroyed immediately at a concentration of 50&#x2013;100&#xa0;mg of extract and in half an hour at a concentration of 20&#xa0;mg of extract. The author also reports that <italic>P. granatum</italic> extract with a concentration of 10%, demonstrated 100% effect against <italic>T. vaginalis</italic> in Diamond media (<xref ref-type="bibr" rid="B34">El-Sherbiny and El Sherbiny, 2011</xref>).</p>
</sec>
<sec id="s6">
<title>Overall Conclusion and Future Perspectives</title>
<p>Complications caused by STDs are essential due to global public health problems, caused by social behaviour, vulnerability conditions that increase the risk of infection with various microorganisms and the risk of HIV infection. Natural bioactive compounds have positive effects against the viability of pathogenic microorganisms, compared to drugs used to treat STDs. They showed inhibitory effects on parasites, fungi, bacteria and viruses.</p>
<p>Future perspectives address the need for translational medicine studies with establishing exact therapeutic doses for humans. Coordinated multicenter clinical trials are also needed to accumulate larger, homogeneous cohorts in the selection of patients with STDs and the severity of their disease. Also, several clinical trials should use a randomized controlled design in order to obtain higher levels of evidence.</p>
<p>Limitations and clinical pitfalls in the clinical therapy of STDs using natural compounds derive from their bioavailability and low absorption, especially for topical application. Therefore, future research on pharmaceutical nanoformulations for ointments or gels as versatile drug delivery systems is needed. The use of drug vectors for the controlled release of bioactive natural compounds in a series of nanoformulations has multiple advantages: non-toxic, biodegradable, can incorporate both hydrophilic and lipophilic chemical compounds, can increase their circulation time, and can reach organs or tissues target, reduce the toxicity of the active substance and often improve its bioavailability. It would also be promising to conduct prospective studies using such bioactive compounds as adjuvants in the management of STDs, which would greatly shorten the production time of drugs with oral administration or topical application. Another limitation of our work derives from the fact that pharmacological evidence and molecular targets of action are gathered from recent meta-analyzes and not from personal data or individualized case presentations. But the included meta-analyzes contain a summary of the latest and most important studies on bioactive compounds effective in the pharmacotherapeutic management of STDs and as a result, based on scientific evidence this may be a strong point highlighting the effects of natural compounds as potential therapeutic agents.</p>
<p>Therefore, future efforts are needed for the generation of new drugs derived from natural compounds against STDs. To be used as safe complementary therapies in the management of STDs, more clinical trials are needed in the future.</p>
</sec>
</body>
<back>
<sec id="s7">
<title>Author Contributions</title>
<p>JS-R, NC-M, AR, JP, WK, JR, AA (6th author): Conceptualization, Formal analysis, Methodology; MB, HM, AA (10th auhtor), PA-Z, MM, PH, PP and GA Data curation, Writing - review &#x26; editing. TT, NC-M, WK, AD and DC: Conceptualization, Formal analysis, Methodology, Writing - original draft, DC: final edits and general revisions. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by CONICYT PIA/APOYO CCTE AFB170007. The project is supported under the program of the Minister of Science and Higher Education under the name &#x201c;Regional Initiative of Excellence&#x201d; in 2019&#x2013;2022 project number: 024/RID/2018/19 and by Medical University of Lublin, Poland, University Grant number: DS 07/2021. This study partially supported by Canakkale Onsekiz Mart University (Scientific Research Projects, ID: FYL-2017&#x2013;1339 and FBA-2017&#x2013;1268).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The reviewer ME-S declared past collaborations with several of the authors MM, AD, JS-R, DC, NC-M to the handling editor.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aiyelaagbe</surname>
<given-names>O. O.</given-names>
</name>
<name>
<surname>Oguntuase</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Arimah</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Adeniyi</surname>
<given-names>B. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>The Antimicrobial Activity of Jatropha Multifida Extracts and Chromatographic Fractions against Sexually Transmitted Infections</article-title>. <source>J.&#x20;Med. Sciences(Faisalabad)</source> <volume>8</volume>, <fpage>143</fpage>&#x2013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.3923/jms.2008.143.147</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amorim</surname>
<given-names>M. M. R. D.</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>L. C.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Tratamento da vaginose bacteriana com gel vaginal de Aroeira (Schinus terebinthifolius Raddi): ensaio cl&#xed;nico randomizado</article-title>. <source>Rev. Bras. Ginecol. Obstet.</source> <volume>25</volume>, <fpage>95</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1590/s0100-72032003000200004</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anagrius</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lore</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Mycoplasma Genitalium: Prevalence, Clinical Significance, and Transmission</article-title>. <source>Sex. Transm. infections</source> <volume>81</volume>, <fpage>458</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2004.012062</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beachler</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Kreimer</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Schiffman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Herrero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wacholder</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>A. C.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Multisite HPV16/18 Vaccine Efficacy against Cervical, Anal, and Oral HPV Infection</article-title>. <source>JNCI.J</source> <volume>108</volume>, <fpage>djv302</fpage>. <pub-id pub-id-type="doi">10.1093/jnci/djv302</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binder</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Weger</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Komericki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kopera</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Treatment of Molluscum Contagiosum with a Pulsed Dye Laser: Pilot Study with 19 Children</article-title>. <source>Jddg</source> <volume>6</volume>, <fpage>121</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1111/j.1610-0387.2007.06556.x</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blostein</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>levin-sparenberg</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Foxman</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Recurrent Vulvovaginal Candidiasis</article-title>. <source>Ann. Epidemiol.</source> <volume>27</volume>, <fpage>575</fpage>&#x2013;<lpage>582</lpage>. <comment>e3</comment>. <pub-id pub-id-type="doi">10.1016/j.annepidem.2017.08.010</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boda</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ilie</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Caruntu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zurac</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Human Papilloma Virus: Apprehending the Link with Carcinogenesis and Unveiling New Research Avenues (Review)</article-title>. <source>Int. J.&#x20;Oncol.</source> <volume>52</volume>, <fpage>637</fpage>&#x2013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.2018.4256</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandelli</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>vieira pde</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Macedo</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Tasca</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Remarkable Anti-trichomonas Vaginalis Activity of Plants Traditionally Used by the Mbya-Guarani Indigenous Group in Brazil</article-title>. <source>Biomed. Res. Int.</source> <volume>2013</volume>, <fpage>826370</fpage>. <pub-id pub-id-type="doi">10.1155/2013/826370</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burkhart</surname>
<given-names>C. G.</given-names>
</name>
<name>
<surname>Burkhart</surname>
<given-names>C. N.</given-names>
</name>
<name>
<surname>Burkhart</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>An Epidemiologic and Therapeutic Reassessment of Scabies</article-title>. <source>CUTIS-NEW YORK-</source> <volume>65</volume>, <fpage>233</fpage>&#x2013;<lpage>242</lpage>. </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buwa</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>van staden</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Antibacterial and Antifungal Activity of Traditional Medicinal Plants Used against Venereal Diseases in South Africa</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>103</volume>, <fpage>139</fpage>&#x2013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2005.09.020</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>C&#xe1;ceres-Castillo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Navarro</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>torres-romero</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Mir&#xf3;n-L&#xf3;pez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>ceballos-cruz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Arana-Arg&#xe1;ez</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Trichomonicidal Activity of a New Anthraquinone Isolated from the Roots of Morinda Panamensis Seem</article-title>. <source>Drug Dev. Res.</source> <volume>80</volume>, <fpage>155</fpage>&#x2013;<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1002/ddr.21504</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Petrakis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Egorov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ishmukhametov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gabibov</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020a</year>). <article-title>Towards Effective COVID-19 V-accines: Updates, P-erspectives and C-hallenges (Review)</article-title>. <source>Int. J.&#x20;Mol. Med.</source> <volume>46</volume>, <fpage>3</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2020.4596</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hartung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Spandidos</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Egorov</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Shtilman</surname>
<given-names>M. I.</given-names>
</name>
<etal/>
</person-group> (<year>2020b</year>). <article-title>COVID-19 Vaccines: Ethical Framework Concerning Human challenge Studies</article-title>. <source>DARU J.&#x20;Pharm. Sci.</source> <volume>28</volume>, <fpage>807</fpage>&#x2013;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1007/s40199-020-00371-8</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rosu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>rosu</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Ianosi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ianosi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zlatian</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>ETIOLOGICAL DIAGNOSIS AND PHARMACOTHERAPEUTIC MANAGEMENT OF PARAPNEUMONIC PLEURISY</article-title>. <source>Farmacia</source> <volume>64</volume>, <fpage>946</fpage>&#x2013;<lpage>952</lpage>. </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Arsene</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Mondal</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020c</year>). <article-title>Recent Advances, Approaches and Challenges in Targeting Pathways for Potential COVID-19 Vaccines Development</article-title>. <source>Immunol. Res.</source> <volume>68</volume>, <fpage>315</fpage>&#x2013;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-020-09154-4</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calonge</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Screening for Syphilis Infection: Recommendation Statement</article-title>. <source>Ann. Fam. Med.</source> <volume>2</volume>, <fpage>362</fpage>&#x2013;<lpage>365</lpage>. <pub-id pub-id-type="doi">10.1370/afm.215</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cargnin</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>P. d. B.</given-names>
</name>
<name>
<surname>Cibulski</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cassel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>R. M. F.</given-names>
</name>
<name>
<surname>Montanha</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Anti-Trichomonas Vaginalis Activity of Hypericum Polyanthemum Extract Obtained by Supercritical Fluid Extraction and Isolated Compounds</article-title>. <source>Parasitol. Int.</source> <volume>62</volume>, <fpage>112</fpage>&#x2013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.parint.2012.10.006</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>cazanave</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Manhart</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>B&#xe9;b&#xe9;ar</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Mycoplasma Genitalium, an Emerging Sexually Transmitted Pathogen</article-title>. <source>M&#xe9;decine et Maladies Infectieuses</source> <volume>42</volume>, <fpage>381</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1016/j.medmal.2012.05.006</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<collab>Centers for Disease Control Prevention</collab> (<year>2007</year>). <article-title>Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>MMWR Recomm Rep.</source> <volume>56</volume>, <fpage>1</fpage>&#x2013;<lpage>24</lpage>. </citation>
</ref>
<ref id="B20">
<citation citation-type="book">
<collab>Centers for Disease Control Prevention</collab> (<year>2011</year>). <source>Sexually Transmitted Disease Surveillance 2010</source>. <publisher-loc>Atlanta</publisher-loc>: <publisher-name>US Department of Health and Human Services</publisher-name>, <fpage>33</fpage>&#x2013;<lpage>44</lpage>.</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<collab>centers for Disease Control Prevention</collab> (<year>2002</year>). <article-title>Sexually Transmitted Diseases Treatment Guidelines 2002</article-title>. <source>Mmwr</source> <volume>51</volume>, <fpage>32</fpage>&#x2013;<lpage>36</lpage>. </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<collab>Centers for Disease Control Prevention</collab> (<year>2005</year>). <article-title>Trends in HIV/AIDS Diagnoses--33 States, 2001-2004</article-title>. <source>MMWR Morb Mortal Wkly Rep.</source> <volume>54</volume>, <fpage>1149</fpage>&#x2013;<lpage>1153</lpage>. </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Aimagambetova</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ukybassova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kongrtay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Azizan</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives</article-title>. <source>J.&#x20;Oncol.</source> <volume>2019</volume>, <fpage>3257939</fpage>. <pub-id pub-id-type="doi">10.1155/2019/3257939</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chesson</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>dunne</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Hariri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Markowitz</surname>
<given-names>L. E.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United&#x20;States</article-title>. <source>Sex. Transm. Dis.</source> <volume>41</volume>, <fpage>660</fpage>&#x2013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1097/olq.0000000000000193</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chosidow</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Scabies</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>354</volume>, <fpage>1718</fpage>&#x2013;<lpage>1727</lpage>. <pub-id pub-id-type="doi">10.1056/nejmcp052784</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chosidow</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Scabies and Pediculosis</article-title>. <source>The Lancet</source> <volume>355</volume>, <fpage>819</fpage>&#x2013;<lpage>826</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(99)09458-1</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>H. G.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>Z. A.</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>K. K.</given-names>
</name>
</person-group> (<year>1983</year>). <article-title>Genital Herpes Simplex Virus Infections: Clinical Manifestations, Course, and Complications</article-title>. <source>Ann. Intern. Med.</source> <volume>98</volume>, <fpage>958</fpage>&#x2013;<lpage>972</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-98-6-958</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crucitti</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Van dyck</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tehe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Abdellati</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vuylsteke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Buve</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Comparison of Culture and Different PCR Assays for Detection of Trichomonas Vaginalis in Self Collected Vaginal Swab Specimens</article-title>. <source>Sex. Transm. Infections</source> <volume>79</volume>, <fpage>393</fpage>&#x2013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1136/sti.79.5.393</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>C&#x103;lina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Rosu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zlatian</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Rosu</surname>
<given-names>A. F.</given-names>
</name>
<name>
<surname>Anghelina</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Antimicrobial Resistance Development Following Surgical Site Infections</article-title>. <source>Mol. Med. Rep.</source> <volume>15</volume>, <fpage>681</fpage>&#x2013;<lpage>688</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2016.6034</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De brum vieira</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Feij&#xf3; Silva</surname>
<given-names>N. L.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>N. P.</given-names>
</name>
<name>
<surname>Da silva</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Da silva</surname>
<given-names>M. V.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>The Caatinga Endemic Manilkara Rufula Possesses Remarkable Activity against Trichomonas Vaginalis and Tritrichomonas Foetus</article-title>. <source>Exp. Parasitol.</source> <volume>173</volume>, <fpage>18</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.exppara.2016.12.006</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De martel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Plummer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vignat</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Worldwide burden of Cancer Attributable to HPV by Site, Country and HPV Type</article-title>. <source>Int. J.&#x20;Cancer</source> <volume>141</volume>, <fpage>664</fpage>&#x2013;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.30716</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desruelles</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cunningham</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Dubois</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Pubic Hair Removal: a Risk Factor for &#x27;minor&#x27; STI Such as Molluscum Contagiosum?</article-title>. <source>Sex. Transm. Infect.</source> <volume>89</volume>, <fpage>216</fpage>. <pub-id pub-id-type="doi">10.1136/sextrans-2012-050982</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Gofita</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ioan</surname>
<given-names>Z. S.</given-names>
</name>
<name>
<surname>Valcea</surname>
<given-names>D. I.</given-names>
</name>
<name>
<surname>Mitrut</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>AUTOIMMUNE DISORDERS DUE TO DOUBLE ANTIVIRAL THERAPY WITH PEGINTERFERON AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS INFECTION</article-title>. <source>Farmacia</source> <volume>64</volume>, <fpage>605</fpage>&#x2013;<lpage>611</lpage>. </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-sherbiny</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>El sherbiny</surname>
<given-names>E. T.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>The Effect of Commiphora Molmol (Myrrh) in Treatment of Trichomoniasis Vaginalis Infection</article-title>. <source>Iran Red Crescent Med. J.</source> <volume>13</volume>, <fpage>480</fpage>&#x2013;<lpage>486</lpage>. </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eleftheriou</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Stratman</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Diagnosis of Atypical Molluscum Contagiosum: The Utility of a Squash Preparation</article-title>. <source>Clin. Med. Res.</source> <volume>9</volume>, <fpage>50</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.3121/cmr.2010.953</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezz eldin</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Badawy</surname>
<given-names>A. F.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>
<italic>In Vitro</italic> anti-Trichomonas Vaginalis Activity of Pistacia Lentiscus mastic and Ocimum Basilicum Essential Oil</article-title>. <source>J.&#x20;Parasit Dis.</source> <volume>39</volume>, <fpage>465</fpage>&#x2013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1007/s12639-013-0374-6</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fakhrieh-kashan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Arbabi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delavari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mohebali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hooshyar</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Induction of Apoptosis by Alcoholic Extract of Combination Verbascum Thapsus and Ginger Officinale on Iranian Isolate of Trichomonas Vaginalis</article-title>. <source>Iran J.&#x20;Parasitol.</source> <volume>13</volume>, <fpage>72</fpage>&#x2013;<lpage>78</lpage>. </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falk</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fredlund</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Signs and Symptoms of Urethritis and Cervicitis Among Women with or without Mycoplasma Genitalium or <italic>Chlamydia trachomatis</italic> Infection</article-title>. <source>Sex. Transm. infections</source> <volume>81</volume>, <fpage>73</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2004.010439</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farias</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Boaretto</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>J.&#x20;I.</given-names>
</name>
<name>
<surname>Brust</surname>
<given-names>F. R.</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>F. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Nectandra as a Renewable Source for (&#x2b;)-&#x3b1;-Bisabolol, an Antibiofilm and Anti-trichomonas Vaginalis Compound</article-title>. <source>Fitoterapia</source> <volume>136</volume>, <fpage>104179</fpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2019.104179</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forcier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Musacchio</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>An Overview of Human Papillomavirus Infection for the Dermatologist: Disease, Diagnosis, Management, and Prevention</article-title>. <source>Dermatol. Ther.</source> <volume>23</volume>, <fpage>458</fpage>&#x2013;<lpage>476</lpage>. <pub-id pub-id-type="doi">10.1111/j.1529-8019.2010.01350.x</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frasson</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Dos santos</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Da silva trentin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Giordani</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Da silva</surname>
<given-names>A. G.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>First Report of Anti-trichomonas Vaginalis Activity of the Medicinal Plant Polygala Decumbens from the Brazilian Semi-arid Region, Caatinga</article-title>. <source>Parasitol. Res.</source> <volume>110</volume>, <fpage>2581</fpage>&#x2013;<lpage>2587</lpage>. <pub-id pub-id-type="doi">10.1007/s00436-011-2787-4</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Quiambao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Noritake</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Potato Peels and Their Bioactive Glycoalkaloids and Phenolic Compounds Inhibit the Growth of Pathogenic Trichomonads</article-title>. <source>J.&#x20;Agric. Food Chem.</source> <volume>66</volume>, <fpage>7942</fpage>&#x2013;<lpage>7947</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.8b01726</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Land</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anti-trichomonad Activities of Different Compounds from Foods, marine Products, and Medicinal Plants: a Review</article-title>. <source>BMC Complement. Med. Therapies</source> <volume>20</volume>, <fpage>271</fpage>. <pub-id pub-id-type="doi">10.1186/s12906-020-03061-9</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galarza</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Donovanosis</article-title>. <source>Dermatol. Peru</source> <volume>10</volume>, <fpage>35</fpage>&#x2013;<lpage>38</lpage>. </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geiger</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Foxman</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Risk Factors for Vulvovaginal Candidiasis</article-title>. <source>Epidemiology</source> <volume>7</volume>, <fpage>182</fpage>&#x2013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1097/00001648-199603000-00013</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geisler</surname>
<given-names>W. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Diagnosis and Management of Uncomplicated <italic>Chlamydia trachomatis</italic> Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines</article-title>. <source>Clin. Infect. Dis.</source> <volume>53</volume>, <fpage>S92</fpage>&#x2013;<lpage>S98</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir698</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geisler</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hook</surname>
<given-names>E. W.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Chlamydial and Gonococcal Infection in Men without Polymorphonuclear Leukocytes on Gram Stain: Implications for Diagnostic Approach and Management</article-title>. <source>Sex. Transm. Dis.</source> <volume>32</volume>, <fpage>630</fpage>&#x2013;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.1097/01.olq.0000175390.45315.a1</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gokalp</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The Inhibition Effect of Garlic-Derived Compounds on Human Immunodeficiency Virus Type 1 and Saquinavir</article-title>. <source>J.&#x20;Biochem. Mol. Toxicol.</source> <volume>32</volume>, <fpage>e22215</fpage>. <pub-id pub-id-type="doi">10.1002/jbt.22215</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottlieb</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Bolan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kamb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Broutet</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Toward Global Prevention of Sexually Transmitted Infections (STIs): the Need for STI Vaccines</article-title>. <source>Vaccine</source> <volume>32</volume>, <fpage>1527</fpage>&#x2013;<lpage>1535</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.087</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wald</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Genital Herpes</article-title>. <source>The Lancet</source> <volume>370</volume>, <fpage>2127</fpage>&#x2013;<lpage>2137</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(07)61908-4</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Aixia</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nancai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Baicalin Suppresses Expression of Chlamydia Protease-like Activity Factor in Hep-2 Cells Infected by <italic>Chlamydia trachomatis</italic>
</article-title>. <source>Fitoterapia</source> <volume>80</volume>, <fpage>448</fpage>&#x2013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.fitote.2009.06.004</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hay</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Steer</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Engelman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Scabies in the Developing World-Iits Prevalence, Complications, and Management</article-title>. <source>Clin. Microbiol. Infect.</source> <volume>18</volume>, <fpage>313</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03798.x</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Appendino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Efferth</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>F&#xfc;rst</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Izzo</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Kayser</surname>
<given-names>O.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Best Practice in Research - Overcoming Common Challenges in Phytopharmacological Research</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>246</volume>, <fpage>112230</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2019.112230</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="book">
<collab>HIV/AIDS J.&#x20;U. N. P. O</collab> (<year>2017</year>). <source>UNAIDS Data 2017</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>UNAIDS</publisher-name>.</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Lukehart</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Syphilis: Using Modern Approaches to Understand an Old Disease</article-title>. <source>J.&#x20;Clin. Invest.</source> <volume>121</volume>, <fpage>4584</fpage>&#x2013;<lpage>4592</lpage>. <pub-id pub-id-type="doi">10.1172/jci57173</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huerta-Reyes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Basualdo</surname>
<given-names>M. d. C.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Jimenez-Estrada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reyes-Chilpa</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2004a</year>). <article-title>HIV-1 Inhibitory Compounds from Calophyllum Brasiliense Leaves</article-title>. <source>Biol. Pharm. Bull.</source> <volume>27</volume>, <fpage>1471</fpage>&#x2013;<lpage>1475</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.27.1471</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huerta-Reyes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Basualdo</surname>
<given-names>M. d. C.</given-names>
</name>
<name>
<surname>Lozada</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jimenez-Estrada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reyes-Chilpa</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2004b</year>). <article-title>HIV-1 Inhibition by Extracts of Clusiaceae Species from Mexico</article-title>. <source>Biol. Pharm. Bull.</source> <volume>27</volume>, <fpage>916</fpage>&#x2013;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1248/bpb.27.916</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jadhav</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mane</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Palshetker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Antimicrobial Activity of Plant Extracts against Sexually Transmitted Pathogens</article-title>. <source>Nat. Product. Res.</source> <volume>29</volume>, <fpage>1562</fpage>&#x2013;<lpage>1566</lpage>. <pub-id pub-id-type="doi">10.1080/14786419.2014.983919</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jensen</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Cusini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moi</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>2016 European Guideline on Mycoplasma Genitalium Infections</article-title>. <source>J.&#x20;Eur. Acad. Dermatol. Venereol.</source> <volume>30</volume>, <fpage>1650</fpage>&#x2013;<lpage>1656</lpage>. <pub-id pub-id-type="doi">10.1111/jdv.13849</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname>
<given-names>V. J.</given-names>
</name>
<name>
<surname>Mabey</surname>
<given-names>D. C.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Global Epidemiology and Control of Trichomonas Vaginalis</article-title>. <source>Curr. Opin. Infect. Dis.</source> <volume>21</volume>, <fpage>56</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1097/qco.0b013e3282f3d999</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kambizi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Afolayan</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Extracts from Aloe Ferox and Withania Somnifera Inhibit Candida Albicans and Neisseria Gonorrhoea</article-title>. <source>Afr. J.&#x20;Biotechnol.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. </citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamng&#x27;ona</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<name>
<surname>Lindsey</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Inhibition of HIV-1 and M-MLV Reverse Transcriptases by a Major Polyphenol (3,4,5 Tri-O-galloylquinic Acid) Present in the Leaves of the South African Resurrection Plant, Myrothamnus Flabellifolia</article-title>. <source>J.&#x20;Enzyme Inhib. Med. Chem.</source> <volume>26</volume>, <fpage>843</fpage>&#x2013;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.3109/14756366.2011.566220</pub-id> </citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kemp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>J.&#x20;J.</given-names>
</name>
<name>
<surname>Lautenschlager</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vall-Mayans</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moi</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>European Guideline for the Management of Chancroid, 2011</article-title>. <source>Int. J.&#x20;STD AIDS</source> <volume>22</volume>, <fpage>241</fpage>&#x2013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1258/ijsa.2010.010432</pub-id> </citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kissinger</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mena</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Levison</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Gatski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>A Randomized Treatment Trial: Single versus 7-Day Dose of Metronidazole for the Treatment of Trichomonas Vaginalis Among HIV-Infected Women</article-title>. <source>J.&#x20;acquired immune deficiency syndromes</source> <volume>55</volume>, <fpage>565</fpage>&#x2013;<lpage>571</lpage>. <pub-id pub-id-type="doi">10.1097/qai.0b013e3181eda955</pub-id>
<italic>1999</italic> </citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klasse</surname>
<given-names>P. J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The Molecular Basis ofHIVentry</article-title>. <source>Cell Microbiol.</source> <volume>14</volume>, <fpage>1183</fpage>&#x2013;<lpage>1192</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2012.01812.x</pub-id> </citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostoff</surname>
<given-names>R. N.</given-names>
</name>
<name>
<surname>Kanduc</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Shoenfeld</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>M. B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Vaccine- and Natural Infection-Induced Mechanisms that Could Modulate Vaccine Safety</article-title>. <source>Toxicol. Rep.</source> <volume>7</volume>, <fpage>1448</fpage>&#x2013;<lpage>1458</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxrep.2020.10.016</pub-id> </citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagerg&#xe5;rd</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>B&#xf6;lin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lindholm</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>On the Evolution of the Sexually Transmitted Bacteria Haemophilus Ducreyi and Klebsiella Granulomatis</article-title>. <source>Ann. N.Y Acad. Sci.</source> <volume>1230</volume>, <fpage>E1</fpage>&#x2013;<lpage>E10</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2011.06193.x</pub-id> </citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langenberg</surname>
<given-names>A. G. M.</given-names>
</name>
<name>
<surname>Corey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Straus</surname>
<given-names>S. E.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>341</volume>, <fpage>1432</fpage>&#x2013;<lpage>1438</lpage>. <pub-id pub-id-type="doi">10.1056/nejm199911043411904</pub-id> </citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fulp</surname>
<given-names>W. J.</given-names>
</name>
<name>
<surname>Giuliano</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Analysis of Overdispersed Count Data: Application to the Human Papillomavirus Infection in Men (HIM) Study</article-title>. <source>Epidemiol. Infect.</source> <volume>140</volume>, <fpage>1087</fpage>&#x2013;<lpage>1094</lpage>. <pub-id pub-id-type="doi">10.1017/s095026881100166x</pub-id> </citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>A. K. C.</given-names>
</name>
<name>
<surname>Barankin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hon</surname>
<given-names>K. L. E.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Molluscum Contagiosum: An Update</article-title>. <source>Recent Pat Inflamm. Allergy Drug Discov.</source> <volume>11</volume>, <fpage>22</fpage>&#x2013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2174/1872213x11666170518114456</pub-id> </citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Chancroid: Clinical Manifestations, Diagnosis, and Management</article-title>. <source>Sex. Transm. infections</source> <volume>79</volume>, <fpage>68</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1136/sti.79.1.68</pub-id> </citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leyte-Lugo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Britton</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Foil</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Todd</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Rivera-Ch&#xe1;vez</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal ( Hydrastis canadensis )</article-title>. <source>Phytochemistry Lett.</source> <volume>20</volume>, <fpage>54</fpage>&#x2013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytol.2017.03.012</pub-id> </citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lister</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Balechandran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ridgway</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Comparison of Azithromycin and Doxycycline in the Treatment of Non-gonococcal Urethritis in Men</article-title>. <source>J.&#x20;Antimicrob. Chemother.</source> <volume>31</volume>, <fpage>185</fpage>&#x2013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1093/jac/31.suppl_e.185</pub-id> </citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Looker</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Magaret</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Vickerman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Newman</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012</article-title>. <source>PloS one</source> <volume>10</volume>, <fpage>e114989</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0114989</pub-id> </citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luke</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Silverberg</surname>
<given-names>N. B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Vertically Transmitted Molluscum Contagiosum Infection</article-title>. <source>Pediatrics</source> <volume>125</volume>, <fpage>e423</fpage>&#x2013;<lpage>e425</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2009-2774</pub-id> </citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mabey</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Epidemiology of STIs: Worldwide</article-title>. <source>Medicine</source> <volume>38</volume>, <fpage>216</fpage>&#x2013;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1016/j.mpmed.2010.01.009</pub-id> </citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mamba</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Adebayo</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Tshikalange</surname>
<given-names>T. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Anti-microbial, Anti-inflammatory and HIV-1 Reverse Transcriptase Activity of Selected South African Plants Used to Treat Sexually Transmitted Diseases</article-title>. <source>Int. J.&#x20;Pharmacognosy Phytochem. Res.</source> <volume>8</volume>, <fpage>1870</fpage>&#x2013;<lpage>1876</lpage>. </citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayta</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gilman</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Calderon</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soto</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Tuero</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>18S Ribosomal DNA-Based PCR for Diagnosis of Trichomonas Vaginalis</article-title>. <source>J.&#x20;Clin. Microbiol.</source> <volume>38</volume>, <fpage>2683</fpage>&#x2013;<lpage>2687</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.38.7.2683-2687.2000</pub-id> </citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melhuish</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lewthwaite</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Natural History of HIV and AIDS</article-title>. <source>Medicine</source> <volume>46</volume>, <fpage>356</fpage>&#x2013;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/j.mpmed.2018.03.010</pub-id> </citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertz</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Benedetti</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Selke</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Corey</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Risk Factors for the Sexual Transmission of Genital Herpes</article-title>. <source>Ann. Intern. Med.</source> <volume>116</volume>, <fpage>197</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-116-3-197</pub-id> </citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meza-Romero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Navarrete-Dechent</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Downey</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Molluscum Contagiosum: an Update and Review of New Perspectives in Etiology, Diagnosis, and Treatment</article-title>. <source>Ccid</source> <volume>12</volume>, <fpage>373</fpage>&#x2013;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.2147/ccid.s187224</pub-id> </citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mongalo</surname>
<given-names>N. I.</given-names>
</name>
<name>
<surname>Mcgaw</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Finnie</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Van Staden</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pharmacological Properties of Extracts from Six South African Medicinal Plants Used to Treat Sexually Transmitted Infections (STIs) and Related Infections</article-title>. <source>South Afr. J.&#x20;Bot.</source> <volume>112</volume>, <fpage>290</fpage>&#x2013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2017.05.031</pub-id> </citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mulaudzi</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Ndhlala</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Finnie</surname>
<given-names>J.&#x20;F.</given-names>
</name>
<name>
<surname>Van Staden</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Antimicrobial Properties and Phenolic Contents of Medicinal Plants Used by the Venda People for Conditions Related to Venereal Diseases</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>135</volume>, <fpage>330</fpage>&#x2013;<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2011.03.022</pub-id> </citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>F. X.</given-names>
</name>
<name>
<surname>de Sanjos&#xe9;</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herrero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Castellsagu&#xe9;</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>K. V.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>348</volume>, <fpage>518</fpage>&#x2013;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1056/nejmoa021641</pub-id> </citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naemi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Asghari</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yousofi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>H. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Chemical Composition of Essential Oil and Anti Trichomonas Activity of Leaf, Stem, and Flower of Rheum Ribes L. Extracts</article-title>. <source>Avicenna J.&#x20;Phytomed</source> <volume>4</volume>, <fpage>191</fpage>&#x2013;<lpage>199</lpage>. </citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naidoo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Van Vuuren</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Van Zyl</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>De Wet</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Plants Traditionally Used Individually and in Combination to Treat Sexually Transmitted Infections in Northern Maputaland, South Africa: Antimicrobial Activity and Cytotoxicity</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>149</volume>, <fpage>656</fpage>&#x2013;<lpage>667</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2013.07.018</pub-id> </citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rowley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vander Hoorn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wijesooriya</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Unemo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting</article-title>. <source>PloS one</source> <volume>10</volume>, <fpage>e0143304</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0143304</pub-id> </citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Farrell</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Donovanosis</article-title>. <source>Sex. Transmitted Infections</source> <volume>78</volume>, <fpage>452</fpage>&#x2013;<lpage>457</lpage>. </citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orion</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Marcos</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Davidovici</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Itch and Scratch: Scabies and Pediculosis</article-title>. <source>Clin. Dermatol.</source> <volume>24</volume>, <fpage>168</fpage>&#x2013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.clindermatol.2005.11.001</pub-id> </citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Gilroy</surname>
<given-names>C. B.</given-names>
</name>
<name>
<surname>Furr</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Taylor-Robinson</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Development and Evaluation of the Polymerase Chain Reaction to detectMycoplasma Genitalium</article-title>. <source>FEMS Microbiol. Lett.</source> <volume>77</volume>, <fpage>199</fpage>&#x2013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.1991.tb04347.x</pub-id> </citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pendota</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Aderogba</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Moyo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mcgaw</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Mulaudzi</surname>
<given-names>R. B.</given-names>
</name>
<name>
<surname>Van Staden</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Antimicrobial, Antioxidant and Cytotoxicity of Isolated Compounds from Leaves of Pappea Capensis</article-title>. <source>South Afr. J.&#x20;Bot.</source> <volume>108</volume>, <fpage>272</fpage>&#x2013;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2016.10.021</pub-id> </citation>
</ref>
<ref id="B92">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Pontari</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2016</year>). &#x201c;<article-title>Inflammation and Anti-inflammatory Therapy in Chronic Prostatitis</article-title>,&#x201d; in <source>Campbell-walsh Urology</source>. Editors <person-group person-group-type="editor">
<name>
<surname>Partin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kavoussi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dmochowski</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wein</surname>
<given-names>A.</given-names>
</name>
</person-group> <edition>eleventh ed.</edition> (<publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Elsevier</publisher-name>). </citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Potroz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>N.-J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Natural Products for the Treatment of Trachoma and <italic>Chlamydia trachomatis</italic>
</article-title>. <source>Molecules</source> <volume>20</volume>, <fpage>4180</fpage>&#x2013;<lpage>4203</lpage>. <pub-id pub-id-type="doi">10.3390/molecules20034180</pub-id> </citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richens</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Donovanosis (Granuloma Inguinale)</article-title>. <source>Sex. Transm. infections</source> <volume>82</volume>, <fpage>iv21</fpage>&#x2013;<lpage>iv22</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2006.023135</pub-id> </citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richens</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>The Diagnosis and Treatment of Donovanosis (Granuloma Inguinale)</article-title>. <source>Sex. Transm. Infections</source> <volume>67</volume>, <fpage>441</fpage>&#x2013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1136/sti.67.6.441</pub-id> </citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roca-M&#xe9;zquita</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Graniel-Sabido</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Moo-Puc</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Leon-D&#xe9;niz</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Gamboa-Le&#xf3;n</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Arjona-Ruiz</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Antiprotozoal Activity of Extracts of Elaeodendron Trichotomum (Celastraceae)</article-title>. <source>Ajtcam</source> <volume>13</volume>, <fpage>162</fpage>&#x2013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.21010/ajtcam.v13i4.21</pub-id> </citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Capanoglu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Adrar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Catalkaya</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shaheen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jaffer</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019a</year>). <article-title>Cucurbits Plants: A Key Emphasis to its Pharmacological Potential</article-title>. <source>Molecules</source> <volume>24</volume>, <fpage>23</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24101854</pub-id> </citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jornet</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>E. P. F.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ramirez-Alarcon</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019b</year>). <article-title>Plant-Derived Bioactives in Oral Mucosal Lesions: A Key Emphasis to Curcumin, Lycopene, Chamomile, Aloe Vera, Green Tea and Coffee Properties</article-title>. <source>Biomolecules</source> <volume>9</volume>, <fpage>23</fpage>. <pub-id pub-id-type="doi">10.3390/biom9030106</pub-id> </citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prakash Mishra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nigam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karazhan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shukla</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kie&#x142;tyka&#x2010;Dadasiewicz</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021a</year>). <article-title>Ficus Plants: State of the Art from a Phytochemical, Pharmacological, and Toxicological Perspective</article-title>. <source>Phytotherapy Res.</source> <volume>35</volume>, <fpage>1187</fpage>&#x2013;<lpage>1217</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.6884</pub-id> </citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Quispe</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chamkhi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>El Omari</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Balahbib</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2021b</year>). <article-title>Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>. <pub-id pub-id-type="doi">10.3389/fphar.2020.592654</pub-id> </citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rescigno</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dettori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Avocado-Soybean Unsaponifiables: A Panoply of Potentialities to Be Exploited</article-title>. <source>BIOMOLECULES</source> <volume>10</volume>, <fpage>20</fpage>. <pub-id pub-id-type="doi">10.3390/biom10010130</pub-id> </citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Capanoglu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Adrar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Catalkaya</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Shaheen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2019c</year>). <article-title>Cucurbita Plants: From Farm to Industry</article-title>. <source>Appl. Sciences-Basel</source> <volume>9</volume>, <fpage>21</fpage>. <pub-id pub-id-type="doi">10.3390/app9163387</pub-id> </citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shetty</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>N. V. A.</given-names>
</name>
<name>
<surname>Zivkovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<etal/>
</person-group> (<year>2019d</year>). <article-title>Veronica Plants-Drifting from Farm to Traditional Healing, Food Application, and Phytopharmacology</article-title>. <source>Molecules</source> <volume>24</volume>, <fpage>35</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24132454</pub-id> </citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiller</surname>
<given-names>J.&#x20;T.</given-names>
</name>
<name>
<surname>Castellsagu&#xe9;</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Garland</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines</article-title>. <source>Vaccine</source> <volume>30</volume>, <fpage>F123</fpage>&#x2013;<lpage>F138</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.108</pub-id> </citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Wudiri</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Trammell</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Nicola</surname>
<given-names>A. V.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor</article-title>. <source>mBio</source> <volume>10</volume>, <fpage>e00732</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1128/mbio.00732-19</pub-id> </citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seleteng-Kose</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Moteetee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Van Vuuren</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Medicinal Plants Used for the Treatment of Sexually Transmitted Infections in the Maseru District, Lesotho: Antimicrobial Validation, Phytochemical and Cytotoxicity Studies</article-title>. <source>South Afr. J.&#x20;Bot.</source> <volume>122</volume>, <fpage>457</fpage>&#x2013;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1016/j.sajb.2019.01.035</pub-id> </citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dey</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Koirala</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shaheen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>El Omari</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Salehi</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cinnamomum Species: Bridging Phytochemistry Knowledge, Pharmacological Properties and Toxicological Safety for Health Benefits</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>. <pub-id pub-id-type="doi">10.3389/fphar.2021.600139</pub-id> </citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharifi-Rad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>C. F.</given-names>
</name>
<name>
<surname>Sharopov</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Karaca</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Sharifi-Rad</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Diet, Lifestyle and Cardiovascular Diseases: Linking Pathophysiology to Cardioprotective Effects of Natural Bioactive Compounds</article-title>. <source>Int. J.&#x20;Environ. Res. Public Health</source> <volume>17</volume>, <fpage>31</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph17072326</pub-id> </citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shokeen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bala</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tandon</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Preliminary Studies on Activity of Ocimum Sanctum, Drynaria Quercifolia, and Annona Squamosa against Neisseria Gonorrhoeae</article-title>. <source>Sex. Transm. Dis.</source> <volume>32</volume>, <fpage>106</fpage>&#x2013;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1097/01.olq.0000152821.23777.90</pub-id> </citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simonart</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>De Maertelaer</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Curettage Treatment for Molluscum Contagiosum: a Follow-Up Survey Study</article-title>. <source>Br. J.&#x20;Dermatol.</source> <volume>159</volume>, <fpage>1144</fpage>&#x2013;<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08833.x</pub-id> </citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobel</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Brooker</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>G. E.</given-names>
</name>
<name>
<surname>Thomason</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Wermeling</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>1995</year>). <article-title>Single Oral Dose Fluconazole Compared with Conventional Clotrimazole Topical Therapy of Candida Vaginitis</article-title>. <source>Am. J.&#x20;Obstet. Gynecol.</source> <volume>172</volume>, <fpage>1263</fpage>&#x2013;<lpage>1268</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9378(95)91490-0</pub-id> </citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobel</surname>
<given-names>J.&#x20;D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Genital Candidiasis</article-title>. <source>Medicine</source> <volume>42</volume>, <fpage>364</fpage>&#x2013;<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1016/j.mpmed.2014.04.006</pub-id> </citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobel</surname>
<given-names>J.&#x20;D.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Recurrent Vulvovaginal Candidiasis</article-title>. <source>Am. J.&#x20;Obstet. Gynecol.</source> <volume>214</volume>, <fpage>15</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2015.06.067</pub-id> </citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanley</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Prophylactic HPV Vaccines: Prospects for Eliminating Ano-Genital Cancer</article-title>. <source>Br. J.&#x20;Cancer</source> <volume>96</volume>, <fpage>1320</fpage>&#x2013;<lpage>1323</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6603695</pub-id> </citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taheri</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jokovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vitorovic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grundmann</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Maroyi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calina</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The Burden of the Serious and Difficult-To-Treat Infections and a New Antibiotic Available: Cefiderocol</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>18</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.578823</pub-id> </citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talwar</surname>
<given-names>G. P.</given-names>
</name>
<name>
<surname>Raghuvanshi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Rattan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Whaley</surname>
<given-names>K. J.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Polyherbal Formulations with Wide Spectrum Antimicrobial Activity against Reproductive Tract Infections and Sexually Transmitted Pathogens</article-title>. <source>Am. J.&#x20;Reprod. Immunol.</source> <volume>43</volume>, <fpage>144</fpage>&#x2013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1111/j.8755-8920.2000.430303.x</pub-id> </citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor-Robinson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>J.&#x20;S.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Mycoplasma Genitalium: from Chrysalis to Multicolored Butterfly</article-title>. <source>Clin. Microbiol. Rev.</source> <volume>24</volume>, <fpage>498</fpage>&#x2013;<lpage>514</lpage>. <pub-id pub-id-type="doi">10.1128/cmr.00006-11</pub-id> </citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiwari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Anti-Trichomonas Activity of Sapindus Saponins, a Candidate for Development as Microbicidal Contraceptive</article-title>. <source>J.&#x20;Antimicrob. Chemother.</source> <volume>62</volume>, <fpage>526</fpage>&#x2013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkn223</pub-id> </citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ungureanu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zlatian</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mitroi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Droca&#x15f;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>&#x162;&#xee;rc&#x103;</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>C&#x103;lina</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>
<italic>Staphylococcus aureus</italic> Colonisation in Patients from a Primary Regional Hospital</article-title>. <source>Mol. Med. Rep.</source> <volume>16</volume>, <fpage>8771</fpage>&#x2013;<lpage>8780</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.7746</pub-id> </citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Der Wouden</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Van Der Sande</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kruithof</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Sollie</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Van Suijlekom-Smit</surname>
<given-names>L. W.</given-names>
</name>
<name>
<surname>Koning</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Interventions for Cutaneous Molluscum Contagiosum</article-title>. <source>Cochrane Database Syst. Rev.</source> <volume>5</volume>, <fpage>Cd004767</fpage>. </citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Vuuren</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>An Antimicrobial Investigation of Plants Used Traditionally in Southern Africa to Treat Sexually Transmitted Infections</article-title>. <source>J.&#x20;Ethnopharmacology</source> <volume>130</volume>, <fpage>552</fpage>&#x2013;<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2010.05.045</pub-id> </citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vazini</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Anti-Trichomonas Vaginalis Activity of Nano Micana Cordifolia and Metronidazole: an <italic>In Vitro</italic> Study</article-title>. <source>J.&#x20;Parasit Dis.</source> <volume>41</volume>, <fpage>1034</fpage>&#x2013;<lpage>1039</lpage>. <pub-id pub-id-type="doi">10.1007/s12639-017-0930-6</pub-id> </citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velho</surname>
<given-names>P. E. N. F.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>E. M. D.</given-names>
</name>
<name>
<surname>Belda Junior</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Donovanosis</article-title>. <source>Braz. J.&#x20;Infect. Dis.</source> <volume>12</volume>, <fpage>521</fpage>&#x2013;<lpage>525</lpage>. <pub-id pub-id-type="doi">10.1590/s1413-86702008000600015</pub-id> </citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wendel</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Erbelding</surname>
<given-names>E. J.</given-names>
</name>
<name>
<surname>Gaydos</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Rompalo</surname>
<given-names>A. M.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Trichomonas vaginalisPolymerase Chain Reaction Compared with Standard Diagnostic and Therapeutic Protocols for Detection and Treatment of Vaginal Trichomoniasis</article-title>. <source>Clin. Infect. Dis.</source> <volume>35</volume>, <fpage>576</fpage>&#x2013;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1086/342060</pub-id> </citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wheeler</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goh</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Dark Ground Microscopy and Treponemal Serological Tests in the Diagnosis of Early Syphilis</article-title>. <source>Sex. Transm. infections</source> <volume>80</volume>, <fpage>411</fpage>&#x2013;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1136/sti.2003.008821</pub-id> </citation>
</ref>
<ref id="B126">
<citation citation-type="web">
<collab>WHO</collab> (<year>2019</year>). <article-title>
<italic>Cervical cancer</italic>
</article-title> [<comment>Online</comment>]. <comment>Available: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/cervical-cancer#tab=tab_1">https://www.who.int/health-topics/cervical-cancer&#x23;tab&#x3d;tab_1</ext-link> (Accessed June 25, 2021)</comment>. </citation>
</ref>
<ref id="B127">
<citation citation-type="book">
<collab>WHO</collab> (<year>2001</year>). <source>Global Prevalence and Incidence of Selected Curable Sexually Transmitted Infections: Overview and estimatesWorld Health Organization (WHO) Report</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</citation>
</ref>
<ref id="B128">
<citation citation-type="book">
<collab>WHO</collab> (<year>2006</year>). <source>Global Strategy for the Prevention and Control of Sexually Transmitted Infections: 2006-2015: Key messagesWorld Health Organization (WHO) Report</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</citation>
</ref>
<ref id="B129">
<citation citation-type="book">
<collab>WHO</collab> (<year>2012</year>). <source>Prevention and Control of Viral Hepatitis Infection: Framework for Global actionWorld Health Organization (WHO) Report</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</citation>
</ref>
<ref id="B130">
<citation citation-type="book">
<collab>WHO</collab> (<year>2018</year>). <source>Report on Global Sexually Transmitted Infection Surveillance 2018</source>. <publisher-loc>Geneva</publisher-loc>.</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Workowski</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines</article-title>. <source>Clin. Infect. Dis.</source> <volume>53</volume>, <fpage>S59</fpage>&#x2013;<lpage>S63</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir694</pub-id> </citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Workowski</surname>
<given-names>K. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines</article-title>. <source>Clin. Infect. Dis.</source> <volume>61</volume>, <fpage>S759</fpage>&#x2013;<lpage>S762</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ771</pub-id> </citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamazaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kishimoto</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shiga</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2003</year>). <article-title>
<italic>In Vitro</italic> inhibitory Effects of tea Polyphenols on the Proliferation of <italic>Chlamydia trachomatis</italic> and Chlamydia Pneumoniae</article-title>. <source>Jpn. J.&#x20;Infect. Dis.</source> <volume>56</volume>, <fpage>143</fpage>&#x2013;<lpage>145</lpage>. </citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zairi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tangy</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Saadi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hani</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>
<italic>In Vitro</italic> activity of Dermaseptin S4 Derivatives against Genital Infections Pathogens</article-title>. <source>Regul. Toxicol. Pharmacol.</source> <volume>50</volume>, <fpage>353</fpage>&#x2013;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2008.01.005</pub-id> </citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zdrodowska-Stefanow</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>K&#x142;osowska</surname>
<given-names>W. M.</given-names>
</name>
<name>
<surname>Ostaszewska-Puchalska</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bu&#x142;hak-Kozio&#x142;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kotowicz</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Ureaplasma Urealyticum and Mycoplasma Hominis Infection in Women with Urogenital Diseases</article-title>. <source>Adv. Med. Sci.</source> <volume>51</volume>, <fpage>250</fpage>&#x2013;<lpage>253</lpage>. </citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Takaishi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Honda</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Coumarins and Bicoumarin from Ferula Sumbul: Anti-HIV Activity and Inhibition of Cytokine Release</article-title>. <source>Phytochemistry</source> <volume>53</volume>, <fpage>689</fpage>&#x2013;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1016/s0031-9422(99)00554-3</pub-id> </citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziaei Hezarjaribi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nadeali</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fakhar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soosaraei</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Medicinal Plants with Anti-trichomonas Vaginalis Activity in Iran: A Systematic Review</article-title>. <source>Iran J.&#x20;Parasitol.</source> <volume>14</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. </citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zlatian</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Balasoiu</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Balasoiu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cristea</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Docea</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Mitrut</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Antimicrobial Resistance in Bacterial Pathogens Among Hospitalised Patients with Severe Invasive Infections</article-title>. <source>Exp. Ther. Med.</source> <volume>16</volume>, <fpage>4499</fpage>&#x2013;<lpage>4510</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2018.6737</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>